EP2055384A1 - Device for identifying constituents in a fluid - Google Patents
Device for identifying constituents in a fluid Download PDFInfo
- Publication number
- EP2055384A1 EP2055384A1 EP07021342A EP07021342A EP2055384A1 EP 2055384 A1 EP2055384 A1 EP 2055384A1 EP 07021342 A EP07021342 A EP 07021342A EP 07021342 A EP07021342 A EP 07021342A EP 2055384 A1 EP2055384 A1 EP 2055384A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- blood
- measuring
- filter
- detection reagent
- opening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012530 fluid Substances 0.000 title claims abstract description 77
- 239000000470 constituent Substances 0.000 title claims description 29
- 238000001514 detection method Methods 0.000 claims abstract description 86
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 82
- 210000004369 blood Anatomy 0.000 claims abstract description 51
- 239000008280 blood Substances 0.000 claims abstract description 51
- 239000000126 substance Substances 0.000 claims abstract description 47
- 210000002966 serum Anatomy 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000007787 solid Substances 0.000 claims abstract description 15
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical group CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 9
- 238000010521 absorption reaction Methods 0.000 claims abstract description 6
- 239000000975 dye Substances 0.000 claims abstract description 6
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960005542 ethidium bromide Drugs 0.000 claims abstract description 5
- 239000007791 liquid phase Substances 0.000 claims abstract description 5
- 230000003287 optical effect Effects 0.000 claims abstract description 4
- 238000005375 photometry Methods 0.000 claims abstract description 4
- 238000005415 bioluminescence Methods 0.000 claims abstract description 3
- 230000029918 bioluminescence Effects 0.000 claims abstract description 3
- 238000004020 luminiscence type Methods 0.000 claims abstract description 3
- 230000003595 spectral effect Effects 0.000 claims abstract description 3
- 238000005259 measurement Methods 0.000 claims description 36
- 238000013022 venting Methods 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 abstract description 7
- 239000007850 fluorescent dye Substances 0.000 abstract description 6
- 108020004707 nucleic acids Proteins 0.000 abstract description 6
- 102000039446 nucleic acids Human genes 0.000 abstract description 6
- 150000007523 nucleic acids Chemical class 0.000 abstract description 6
- 230000003993 interaction Effects 0.000 abstract description 4
- 239000012907 medicinal substance Substances 0.000 abstract 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 62
- 210000002381 plasma Anatomy 0.000 description 48
- -1 polyethylene terephthalate Polymers 0.000 description 24
- 239000000306 component Substances 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 12
- 239000012528 membrane Substances 0.000 description 11
- 239000011575 calcium Substances 0.000 description 10
- 239000005090 green fluorescent protein Substances 0.000 description 10
- 229940127121 immunoconjugate Drugs 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- BGWLYQZDNFIFRX-UHFFFAOYSA-N 5-[3-[2-[3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propylamino]ethylamino]propyl]-6-phenylphenanthridin-5-ium-3,8-diamine;dichloride Chemical compound [Cl-].[Cl-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCNCCNCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 BGWLYQZDNFIFRX-UHFFFAOYSA-N 0.000 description 9
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 8
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 108010004469 allophycocyanin Proteins 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000004698 Polyethylene Substances 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229920000573 polyethylene Polymers 0.000 description 7
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 6
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 6
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- QOFZZTBWWJNFCA-UHFFFAOYSA-N texas red-X Chemical compound [O-]S(=O)(=O)C1=CC(S(=O)(=O)NCCCCCC(=O)O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 QOFZZTBWWJNFCA-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- AUUIARVPJHGTSA-UHFFFAOYSA-N 3-(aminomethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(CN)=CC2=C1 AUUIARVPJHGTSA-UHFFFAOYSA-N 0.000 description 5
- UNGMOMJDNDFGJG-UHFFFAOYSA-N 5-carboxy-X-rhodamine Chemical compound [O-]C(=O)C1=CC(C(=O)O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 UNGMOMJDNDFGJG-UHFFFAOYSA-N 0.000 description 5
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 5
- FGBAVQUHSKYMTC-UHFFFAOYSA-M LDS 751 dye Chemical compound [O-]Cl(=O)(=O)=O.C1=CC2=CC(N(C)C)=CC=C2[N+](CC)=C1C=CC=CC1=CC=C(N(C)C)C=C1 FGBAVQUHSKYMTC-UHFFFAOYSA-M 0.000 description 5
- BOLJGYHEBJNGBV-UHFFFAOYSA-J PoPo-1 Chemical compound [I-].[I-].[I-].[I-].O1C2=CC=CC=C2[N+](C)=C1C=C1C=CN(CCC[N+](C)(C)CCC[N+](C)(C)CCCN2C=CC(=CC3=[N+](C4=CC=CC=C4O3)C)C=C2)C=C1 BOLJGYHEBJNGBV-UHFFFAOYSA-J 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 239000012503 blood component Substances 0.000 description 5
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 239000003365 glass fiber Substances 0.000 description 5
- 229960002378 oftasceine Drugs 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 4
- YMZMTOFQCVHHFB-UHFFFAOYSA-N 5-carboxytetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C([O-])=O YMZMTOFQCVHHFB-UHFFFAOYSA-N 0.000 description 4
- VWOLRKMFAJUZGM-UHFFFAOYSA-N 6-carboxyrhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC(C(O)=O)=CC=C1C(=O)OCC VWOLRKMFAJUZGM-UHFFFAOYSA-N 0.000 description 4
- IHHSSHCBRVYGJX-UHFFFAOYSA-N 6-chloro-2-methoxyacridin-9-amine Chemical compound C1=C(Cl)C=CC2=C(N)C3=CC(OC)=CC=C3N=C21 IHHSSHCBRVYGJX-UHFFFAOYSA-N 0.000 description 4
- WEJVZSAYICGDCK-UHFFFAOYSA-N Alexa Fluor 430 Chemical compound CC[NH+](CC)CC.CC1(C)C=C(CS([O-])(=O)=O)C2=CC=3C(C(F)(F)F)=CC(=O)OC=3C=C2N1CCCCCC(=O)ON1C(=O)CCC1=O WEJVZSAYICGDCK-UHFFFAOYSA-N 0.000 description 4
- 239000012114 Alexa Fluor 647 Substances 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- GRRMZXFOOGQMFA-UHFFFAOYSA-J YoYo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2O1 GRRMZXFOOGQMFA-UHFFFAOYSA-J 0.000 description 4
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 4
- 108010082025 cyan fluorescent protein Proteins 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000007039 two-step reaction Methods 0.000 description 4
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 3
- RUVJFMSQTCEAAB-UHFFFAOYSA-M 2-[3-[5,6-dichloro-1,3-bis[[4-(chloromethyl)phenyl]methyl]benzimidazol-2-ylidene]prop-1-enyl]-3-methyl-1,3-benzoxazol-3-ium;chloride Chemical compound [Cl-].O1C2=CC=CC=C2[N+](C)=C1C=CC=C(N(C1=CC(Cl)=C(Cl)C=C11)CC=2C=CC(CCl)=CC=2)N1CC1=CC=C(CCl)C=C1 RUVJFMSQTCEAAB-UHFFFAOYSA-M 0.000 description 3
- 239000012103 Alexa Fluor 488 Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- QBKMWMZYHZILHF-UHFFFAOYSA-L Po-Pro-1 Chemical compound [I-].[I-].O1C2=CC=CC=C2[N+](C)=C1C=C1C=CN(CCC[N+](C)(C)C)C=C1 QBKMWMZYHZILHF-UHFFFAOYSA-L 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DPXHITFUCHFTKR-UHFFFAOYSA-L To-Pro-1 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 DPXHITFUCHFTKR-UHFFFAOYSA-L 0.000 description 3
- MZZINWWGSYUHGU-UHFFFAOYSA-J ToTo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3S2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2S1 MZZINWWGSYUHGU-UHFFFAOYSA-J 0.000 description 3
- ULHRKLSNHXXJLO-UHFFFAOYSA-L Yo-Pro-1 Chemical compound [I-].[I-].C1=CC=C2C(C=C3N(C4=CC=CC=C4O3)C)=CC=[N+](CCC[N+](C)(C)C)C2=C1 ULHRKLSNHXXJLO-UHFFFAOYSA-L 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- IDMLRIMDYVWWRJ-UHFFFAOYSA-N calcium crimson Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC(NS(=O)(=O)C=2C=C(C(C=3C4=CC=5CCCN6CCCC(C=56)=C4OC4=C5C6=[N+](CCC5)CCCC6=CC4=3)=CC=2)S([O-])(=O)=O)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O IDMLRIMDYVWWRJ-UHFFFAOYSA-N 0.000 description 3
- TUESWZZJYCLFNL-DAFODLJHSA-N chembl1301 Chemical compound C1=CC(C(=N)N)=CC=C1\C=C\C1=CC=C(C(N)=N)C=C1O TUESWZZJYCLFNL-DAFODLJHSA-N 0.000 description 3
- YJHDFAAFYNRKQE-YHPRVSEPSA-L disodium;5-[[4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-[(e)-2-[4-[[4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfonatophenyl]ethenyl]benzenesulfonate Chemical compound [Na+].[Na+].N=1C(NC=2C=C(C(\C=C\C=3C(=CC(NC=4N=C(N=C(NC=5C=CC=CC=5)N=4)N(CCO)CCO)=CC=3)S([O-])(=O)=O)=CC=2)S([O-])(=O)=O)=NC(N(CCO)CCO)=NC=1NC1=CC=CC=C1 YJHDFAAFYNRKQE-YHPRVSEPSA-L 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 229950005911 hydroxystilbamidine Drugs 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- IKEOZQLIVHGQLJ-UHFFFAOYSA-M mitoTracker Red Chemical compound [Cl-].C1=CC(CCl)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 IKEOZQLIVHGQLJ-UHFFFAOYSA-M 0.000 description 3
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 3
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 3
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 2
- JNGRENQDBKMCCR-UHFFFAOYSA-N 2-(3-amino-6-iminoxanthen-9-yl)benzoic acid;hydrochloride Chemical compound [Cl-].C=12C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O JNGRENQDBKMCCR-UHFFFAOYSA-N 0.000 description 2
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 2
- ZVDGOJFPFMINBM-UHFFFAOYSA-N 3-(6-methoxyquinolin-1-ium-1-yl)propane-1-sulfonate Chemical compound [O-]S(=O)(=O)CCC[N+]1=CC=CC2=CC(OC)=CC=C21 ZVDGOJFPFMINBM-UHFFFAOYSA-N 0.000 description 2
- NJIRSTSECXKPCO-UHFFFAOYSA-M 3-[n-methyl-4-[2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]anilino]propanenitrile;chloride Chemical compound [Cl-].C1=CC(N(CCC#N)C)=CC=C1\C=C\C1=[N+](C)C2=CC=CC=C2C1(C)C NJIRSTSECXKPCO-UHFFFAOYSA-M 0.000 description 2
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 2
- YJCCSLGGODRWKK-NSCUHMNNSA-N 4-Acetamido-4'-isothiocyanostilbene-2,2'-disulphonic acid Chemical compound OS(=O)(=O)C1=CC(NC(=O)C)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YJCCSLGGODRWKK-NSCUHMNNSA-N 0.000 description 2
- DJFNQJJTTPMBIL-UHFFFAOYSA-N 7-nitrobenzoxadiazole-6-aminohexanoic acid Chemical compound OC(=O)CCCCCNC1=CC=C([N+]([O-])=O)C2=NON=C12 DJFNQJJTTPMBIL-UHFFFAOYSA-N 0.000 description 2
- IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 2
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- 239000012109 Alexa Fluor 568 Substances 0.000 description 2
- 239000012110 Alexa Fluor 594 Substances 0.000 description 2
- 239000012111 Alexa Fluor 610 Substances 0.000 description 2
- 239000012112 Alexa Fluor 633 Substances 0.000 description 2
- 239000012115 Alexa Fluor 660 Substances 0.000 description 2
- 239000012116 Alexa Fluor 680 Substances 0.000 description 2
- 239000012117 Alexa Fluor 700 Substances 0.000 description 2
- 239000012118 Alexa Fluor 750 Substances 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- UIZZRDIAIPYKJZ-UHFFFAOYSA-J BoBo-3 Chemical compound [I-].[I-].[I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=CC=C1C=CN(CCC[N+](C)(C)CCC[N+](C)(C)CCCN2C=CC(=CC=CC3=[N+](C4=CC=CC=C4S3)C)C=C2)C=C1 UIZZRDIAIPYKJZ-UHFFFAOYSA-J 0.000 description 2
- BRDJPCFGLMKJRU-UHFFFAOYSA-N DDAO Chemical compound ClC1=C(O)C(Cl)=C2C(C)(C)C3=CC(=O)C=CC3=NC2=C1 BRDJPCFGLMKJRU-UHFFFAOYSA-N 0.000 description 2
- 102220566469 GDNF family receptor alpha-1_S65T_mutation Human genes 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 208000004221 Multiple Trauma Diseases 0.000 description 2
- 208000023637 Multiple injury Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- AWZJFZMWSUBJAJ-UHFFFAOYSA-N OG-514 dye Chemical compound OC(=O)CSC1=C(F)C(F)=C(C(O)=O)C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)=C1F AWZJFZMWSUBJAJ-UHFFFAOYSA-N 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QHNORJFCVHUPNH-UHFFFAOYSA-L To-Pro-3 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=CC=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 QHNORJFCVHUPNH-UHFFFAOYSA-L 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 108091005971 Wild-type GFP Proteins 0.000 description 2
- ZVUUXEGAYWQURQ-UHFFFAOYSA-L Yo-Pro-3 Chemical compound [I-].[I-].O1C2=CC=CC=C2[N+](C)=C1C=CC=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 ZVUUXEGAYWQURQ-UHFFFAOYSA-L 0.000 description 2
- JSBNEYNPYQFYNM-UHFFFAOYSA-J YoYo-3 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=CC=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC(=[N+](C)C)CCCC(=[N+](C)C)CC[N+](C1=CC=CC=C11)=CC=C1C=CC=C1N(C)C2=CC=CC=C2O1 JSBNEYNPYQFYNM-UHFFFAOYSA-J 0.000 description 2
- ZYVSOIYQKUDENJ-UHFFFAOYSA-N [6-[[6-[4-[4-(5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl)oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-7-(3,4-dihydroxy-1-methoxy-2-oxopentyl)-4,10-dihydroxy-3-methyl-5-oxo-7,8-dihydro-6h-anthracen-2-yl]oxy]-4-(4-hydroxy-5-methoxy-6 Chemical compound CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(OC(C)=O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1OC(C)=O)CC1OC1CC(O)C(OC)C(C)O1 ZYVSOIYQKUDENJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- NUFNQYOELLVIPL-UHFFFAOYSA-N acifluorfen Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(OC=2C(=CC(=CC=2)C(F)(F)F)Cl)=C1 NUFNQYOELLVIPL-UHFFFAOYSA-N 0.000 description 2
- IVHDZUFNZLETBM-IWSIBTJSSA-N acridine red 3B Chemical compound [Cl-].C1=C\C(=[NH+]/C)C=C2OC3=CC(NC)=CC=C3C=C21 IVHDZUFNZLETBM-IWSIBTJSSA-N 0.000 description 2
- 229940023020 acriflavine Drugs 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- AMKVJCBQCWSOLQ-UHFFFAOYSA-H calcium green 1 Chemical compound [K+].[K+].[K+].[K+].[K+].[K+].[O-]C(=O)CN(CC([O-])=O)C1=CC=CC=C1OCCOC1=CC(NC(=O)C=2C=C3C(C4(C5=CC(Cl)=C([O-])C=C5OC5=CC([O-])=C(Cl)C=C54)OC3=O)=CC=2)=CC=C1N(CC([O-])=O)CC([O-])=O AMKVJCBQCWSOLQ-UHFFFAOYSA-H 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000013013 elastic material Substances 0.000 description 2
- 108010045262 enhanced cyan fluorescent protein Proteins 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 2
- 229940011411 erythrosine Drugs 0.000 description 2
- 235000012732 erythrosine Nutrition 0.000 description 2
- 239000004174 erythrosine Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- DVGHHMFBFOTGLM-UHFFFAOYSA-L fluorogold Chemical compound F[Au][Au]F DVGHHMFBFOTGLM-UHFFFAOYSA-L 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000009830 intercalation Methods 0.000 description 2
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 2
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 2
- NGCVJRFIBJVSFI-UHFFFAOYSA-I magnesium green Chemical compound [K+].[K+].[K+].[K+].[K+].C1=C(N(CC([O-])=O)CC([O-])=O)C(OCC(=O)[O-])=CC(NC(=O)C=2C=C3C(C4(C5=CC(Cl)=C([O-])C=C5OC5=CC([O-])=C(Cl)C=C54)OC3=O)=CC=2)=C1 NGCVJRFIBJVSFI-UHFFFAOYSA-I 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- HQCYVSPJIOJEGA-UHFFFAOYSA-N methoxycoumarin Chemical compound C1=CC=C2OC(=O)C(OC)=CC2=C1 HQCYVSPJIOJEGA-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- AHEWZZJEDQVLOP-UHFFFAOYSA-N monobromobimane Chemical compound BrCC1=C(C)C(=O)N2N1C(C)=C(C)C2=O AHEWZZJEDQVLOP-UHFFFAOYSA-N 0.000 description 2
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 2
- AFAIELJLZYUNPW-UHFFFAOYSA-N pararosaniline free base Chemical compound C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=N)C=C1 AFAIELJLZYUNPW-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- INCIMLINXXICKS-UHFFFAOYSA-M pyronin Y Chemical compound [Cl-].C1=CC(=[N+](C)C)C=C2OC3=CC(N(C)C)=CC=C3C=C21 INCIMLINXXICKS-UHFFFAOYSA-M 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 2
- 229940043267 rhodamine b Drugs 0.000 description 2
- 239000010979 ruby Substances 0.000 description 2
- 229910001750 ruby Inorganic materials 0.000 description 2
- ZSOMPVKQDGLTOT-UHFFFAOYSA-J sodium green Chemical compound C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C.COC=1C=C(NC(=O)C=2C=C(C(=CC=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC([O-])=C(Cl)C=C32)C([O-])=O)C(OC)=CC=1N(CCOCC1)CCOCCOCCN1C(C(=C1)OC)=CC(OC)=C1NC(=O)C1=CC=C(C2=C3C=C(Cl)C(=O)C=C3OC3=CC([O-])=C(Cl)C=C32)C(C([O-])=O)=C1 ZSOMPVKQDGLTOT-UHFFFAOYSA-J 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 2
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- LORKUZBPMQEQET-UHFFFAOYSA-M (2e)-1,3,3-trimethyl-2-[(2z)-2-(1-methyl-2-phenylindol-1-ium-3-ylidene)ethylidene]indole;chloride Chemical compound [Cl-].CC1(C)C2=CC=CC=C2N(C)\C1=C/C=C(C1=CC=CC=C1[N+]=1C)/C=1C1=CC=CC=C1 LORKUZBPMQEQET-UHFFFAOYSA-M 0.000 description 1
- RJKBJEZZABBYBA-DVKNGEFBSA-N (2s,3r,4s,5s,6r)-5-amino-6-methyloxane-2,3,4-triol Chemical compound C[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1N RJKBJEZZABBYBA-DVKNGEFBSA-N 0.000 description 1
- YXZBQCQAYNRRFP-IEBWSBKVSA-N (4-amino-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)-[6-[[(3s,4r)-4-(4-fluorophenyl)oxolan-3-yl]amino]pyrazin-2-yl]methanone Chemical compound C1([C@H]2COC[C@H]2NC=2C=NC=C(N=2)C(=O)C2=CN(C3=NC=NC(N)=C32)C(C)C)=CC=C(F)C=C1 YXZBQCQAYNRRFP-IEBWSBKVSA-N 0.000 description 1
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 1
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- CTTVWDKXMPBZMQ-UHFFFAOYSA-N 1-[6-(dimethylamino)naphthalen-2-yl]undecan-1-one Chemical compound CCCCCCCCCCC(=O)c1ccc2cc(ccc2c1)N(C)C CTTVWDKXMPBZMQ-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- IXZONVAEGFOVSF-UHFFFAOYSA-N 2-(5'-chloro-2'-phosphoryloxyphenyl)-6-chloro-4-(3H)-quinazolinone Chemical compound OP(O)(=O)OC1=CC=C(Cl)C=C1C1=NC(=O)C2=CC(Cl)=CC=C2N1 IXZONVAEGFOVSF-UHFFFAOYSA-N 0.000 description 1
- ALVZYHNBPIMLFM-UHFFFAOYSA-N 2-[4-[2-(4-carbamimidoylphenoxy)ethoxy]phenyl]-1h-indole-6-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(C(=N)N)=CC=C1OCCOC1=CC=C(C=2NC3=CC(=CC=C3C=2)C(N)=N)C=C1 ALVZYHNBPIMLFM-UHFFFAOYSA-N 0.000 description 1
- PDURUKZNVHEHGO-UHFFFAOYSA-N 2-[6-[bis(carboxymethyl)amino]-5-(carboxymethoxy)-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylic acid Chemical compound O1C=2C=C(N(CC(O)=O)CC(O)=O)C(OCC(=O)O)=CC=2C=C1C1=NC=C(C(O)=O)O1 PDURUKZNVHEHGO-UHFFFAOYSA-N 0.000 description 1
- RJPSHDMGSVVHFA-UHFFFAOYSA-N 2-[carboxymethyl-[(7-hydroxy-4-methyl-2-oxochromen-8-yl)methyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C=CC2=C1OC(=O)C=C2C RJPSHDMGSVVHFA-UHFFFAOYSA-N 0.000 description 1
- UCSBOFLEOACXIR-UHFFFAOYSA-N 2-benzyl-8-(cyclopentylmethyl)-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3-ol Chemical compound Oc1c(Cc2ccccc2)nc2c(CC3CCCC3)nc(cn12)-c1ccc(O)cc1 UCSBOFLEOACXIR-UHFFFAOYSA-N 0.000 description 1
- WFOTVGYJMFZMTD-UHFFFAOYSA-N 3',10'-dihydroxyspiro[2-benzofuran-3,7'-benzo[c]xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C(C=CC=1C3=CC=C(O)C=1)=C3OC1=CC(O)=CC=C21 WFOTVGYJMFZMTD-UHFFFAOYSA-N 0.000 description 1
- KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 description 1
- HAPJROQJVSPKCJ-UHFFFAOYSA-N 3-[4-[2-[6-(dibutylamino)naphthalen-2-yl]ethenyl]pyridin-1-ium-1-yl]propane-1-sulfonate Chemical compound C1=CC2=CC(N(CCCC)CCCC)=CC=C2C=C1C=CC1=CC=[N+](CCCS([O-])(=O)=O)C=C1 HAPJROQJVSPKCJ-UHFFFAOYSA-N 0.000 description 1
- IXFSUSNUALIXLU-UHFFFAOYSA-N 3-[4-[2-[6-(dioctylamino)naphthalen-2-yl]ethenyl]pyridin-1-ium-1-yl]propane-1-sulfonate Chemical compound C1=CC2=CC(N(CCCCCCCC)CCCCCCCC)=CC=C2C=C1C=CC1=CC=[N+](CCCS([O-])(=O)=O)C=C1 IXFSUSNUALIXLU-UHFFFAOYSA-N 0.000 description 1
- CPDHBIMOKOHWDD-UHFFFAOYSA-L 3-[4-[4-[4-(diethylamino)phenyl]buta-1,3-dienyl]pyridin-1-ium-1-yl]propyl-triethylazanium;dibromide Chemical compound [Br-].[Br-].C1=CC(N(CC)CC)=CC=C1C=CC=CC1=CC=[N+](CCC[N+](CC)(CC)CC)C=C1 CPDHBIMOKOHWDD-UHFFFAOYSA-L 0.000 description 1
- QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical compound C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 description 1
- PQJVKBUJXQTCGG-UHFFFAOYSA-N 3-n,6-n-dibenzylacridine-3,6-diamine;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CNC(C=C1N=C2C=3)=CC=C1C=C2C=CC=3NCC1=CC=CC=C1 PQJVKBUJXQTCGG-UHFFFAOYSA-N 0.000 description 1
- YSCNMFDFYJUPEF-OWOJBTEDSA-N 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-OWOJBTEDSA-N 0.000 description 1
- LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 1
- YPGZWUVVEWKKDQ-UHFFFAOYSA-M 4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide Chemical compound [I-].C1=CC(N(CCCCCCCCCCCCCCCC)CCCCCCCCCCCCCCCC)=CC=C1C=CC1=CC=[N+](C)C=C1 YPGZWUVVEWKKDQ-UHFFFAOYSA-M 0.000 description 1
- YOQMJMHTHWYNIO-UHFFFAOYSA-N 4-[6-[16-[2-(2,4-dicarboxyphenyl)-5-methoxy-1-benzofuran-6-yl]-1,4,10,13-tetraoxa-7,16-diazacyclooctadec-7-yl]-5-methoxy-1-benzofuran-2-yl]benzene-1,3-dicarboxylic acid Chemical compound COC1=CC=2C=C(C=3C(=CC(=CC=3)C(O)=O)C(O)=O)OC=2C=C1N(CCOCCOCC1)CCOCCOCCN1C(C(=CC=1C=2)OC)=CC=1OC=2C1=CC=C(C(O)=O)C=C1C(O)=O YOQMJMHTHWYNIO-UHFFFAOYSA-N 0.000 description 1
- NZVGXJAQIQJIOY-UHFFFAOYSA-N 4-[6-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-benzimidazol-2-yl]benzenesulfonamide;trihydrochloride Chemical compound Cl.Cl.Cl.C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(=CC=3)S(N)(=O)=O)C2=C1 NZVGXJAQIQJIOY-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- JMHHECQPPFEVMU-UHFFFAOYSA-N 5-(dimethylamino)naphthalene-1-sulfonyl fluoride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(F)(=O)=O JMHHECQPPFEVMU-UHFFFAOYSA-N 0.000 description 1
- IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 1
- XYJODUBPWNZLML-UHFFFAOYSA-N 5-ethyl-6-phenyl-6h-phenanthridine-3,8-diamine Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2N(CC)C1C1=CC=CC=C1 XYJODUBPWNZLML-UHFFFAOYSA-N 0.000 description 1
- DBMJYWPMRSOUGB-UHFFFAOYSA-N 5-hexyl-6-phenylphenanthridin-5-ium-3,8-diamine;iodide Chemical compound [I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCCCCC)=C1C1=CC=CC=C1 DBMJYWPMRSOUGB-UHFFFAOYSA-N 0.000 description 1
- ZMERMCRYYFRELX-UHFFFAOYSA-N 5-{[2-(iodoacetamido)ethyl]amino}naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1NCCNC(=O)CI ZMERMCRYYFRELX-UHFFFAOYSA-N 0.000 description 1
- VDBJCDWTNCKRTF-UHFFFAOYSA-N 6'-hydroxyspiro[2-benzofuran-3,9'-9ah-xanthene]-1,3'-dione Chemical compound O1C(=O)C2=CC=CC=C2C21C1C=CC(=O)C=C1OC1=CC(O)=CC=C21 VDBJCDWTNCKRTF-UHFFFAOYSA-N 0.000 description 1
- HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 description 1
- WVLHHJGFWORTSI-UHFFFAOYSA-N 6-carboxy-2',4,7,7'-tetrachlorofluorescein succinimiyl ester Chemical compound C1=2C=C(Cl)C(O)=CC=2OC2=CC(O)=C(Cl)C=C2C21OC(=O)C(C(=C1)Cl)=C2C(Cl)=C1C(=O)ON1C(=O)CCC1=O WVLHHJGFWORTSI-UHFFFAOYSA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- WJOLQGAMGUBOFS-UHFFFAOYSA-N 8-(cyclopentylmethyl)-2-[(4-fluorophenyl)methyl]-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3-ol Chemical compound Oc1c(Cc2ccc(F)cc2)nc2c(CC3CCCC3)nc(cn12)-c1ccc(O)cc1 WJOLQGAMGUBOFS-UHFFFAOYSA-N 0.000 description 1
- YBLMZJSGNQTCLU-UHFFFAOYSA-N 8-(cyclopentylmethyl)-6-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)methyl]imidazo[1,2-a]pyrazin-3-ol Chemical compound Oc1c(Cc2ccc(O)cc2)nc2c(CC3CCCC3)nc(cn12)-c1ccc(O)cc1 YBLMZJSGNQTCLU-UHFFFAOYSA-N 0.000 description 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
- MEMQQZHHXCOKGG-UHFFFAOYSA-N 8-benzyl-2-[(4-fluorophenyl)methyl]-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3-ol Chemical compound Oc1c(Cc2ccc(F)cc2)nc2c(Cc3ccccc3)nc(cn12)-c1ccc(O)cc1 MEMQQZHHXCOKGG-UHFFFAOYSA-N 0.000 description 1
- ONVKEAHBFKWZHK-UHFFFAOYSA-N 8-benzyl-6-(4-hydroxyphenyl)-2-(naphthalen-1-ylmethyl)imidazo[1,2-a]pyrazin-3-ol Chemical compound Oc1c(Cc2cccc3ccccc23)nc2c(Cc3ccccc3)nc(cn12)-c1ccc(O)cc1 ONVKEAHBFKWZHK-UHFFFAOYSA-N 0.000 description 1
- SGAOZXGJGQEBHA-UHFFFAOYSA-N 82344-98-7 Chemical compound C1CCN2CCCC(C=C3C4(OC(C5=CC(=CC=C54)N=C=S)=O)C4=C5)=C2C1=C3OC4=C1CCCN2CCCC5=C12 SGAOZXGJGQEBHA-UHFFFAOYSA-N 0.000 description 1
- TUCVPZNBGBRVRL-UHFFFAOYSA-N 9'-chloro-3',10'-dihydroxyspiro[2-benzofuran-3,7'-benzo[c]xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=CC2=CC(O)=CC=C21 TUCVPZNBGBRVRL-UHFFFAOYSA-N 0.000 description 1
- ICISKFRDNHZCKS-UHFFFAOYSA-N 9-(4-aminophenyl)-2-methylacridin-3-amine;nitric acid Chemical compound O[N+]([O-])=O.C12=CC=CC=C2N=C2C=C(N)C(C)=CC2=C1C1=CC=C(N)C=C1 ICISKFRDNHZCKS-UHFFFAOYSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- MWNLTKCQHFZFHN-UHFFFAOYSA-N CBQCA reagent Chemical compound C1=CC(C(=O)O)=CC=C1C(=O)C1=CC2=CC=CC=C2N=C1C=O MWNLTKCQHFZFHN-UHFFFAOYSA-N 0.000 description 1
- 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 description 1
- 101710205625 Capsid protein p24 Proteins 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 108091005941 EBFP Proteins 0.000 description 1
- 108091005942 ECFP Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 102220566467 GDNF family receptor alpha-1_S65A_mutation Human genes 0.000 description 1
- 102220566453 GDNF family receptor alpha-1_Y66F_mutation Human genes 0.000 description 1
- 102220566451 GDNF family receptor alpha-1_Y66H_mutation Human genes 0.000 description 1
- 102220566455 GDNF family receptor alpha-1_Y66W_mutation Human genes 0.000 description 1
- FEUPVVCGQLNXNP-IRXDYDNUSA-N Gly-Phe-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FEUPVVCGQLNXNP-IRXDYDNUSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- 101710082837 Ice-structuring protein Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YDIKCZBMBPOGFT-PWUSVEHZSA-N Malvidin 3-galactoside Chemical compound [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)=C1 YDIKCZBMBPOGFT-PWUSVEHZSA-N 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 1
- 238000010826 Nissl staining Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 101800000891 Phallacidin Proteins 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 230000010748 Photoabsorption Effects 0.000 description 1
- CZQJZBNARVNSLQ-UHFFFAOYSA-L Po-Pro-3 Chemical compound [I-].[I-].O1C2=CC=CC=C2[N+](C)=C1C=CC=C1C=CN(CCC[N+](C)(C)C)C=C1 CZQJZBNARVNSLQ-UHFFFAOYSA-L 0.000 description 1
- GYPIAQJSRPTNTI-UHFFFAOYSA-J PoPo-3 Chemical compound [I-].[I-].[I-].[I-].O1C2=CC=CC=C2[N+](C)=C1C=CC=C1C=CN(CCC[N+](C)(C)CCC[N+](C)(C)CCCN2C=CC(=CC=CC3=[N+](C4=CC=CC=C4O3)C)C=C2)C=C1 GYPIAQJSRPTNTI-UHFFFAOYSA-J 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- PXUQTDZNOHRWLI-QOPOCTTISA-O Primulin Natural products O(C)c1c(O)c(OC)cc(-c2c(O[C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O3)cc3c(O)cc(O)cc3[o+]2)c1 PXUQTDZNOHRWLI-QOPOCTTISA-O 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- BDJDTKYGKHEMFF-UHFFFAOYSA-M QSY7 succinimidyl ester Chemical compound [Cl-].C=1C=C2C(C=3C(=CC=CC=3)S(=O)(=O)N3CCC(CC3)C(=O)ON3C(CCC3=O)=O)=C3C=C\C(=[N+](\C)C=4C=CC=CC=4)C=C3OC2=CC=1N(C)C1=CC=CC=C1 BDJDTKYGKHEMFF-UHFFFAOYSA-M 0.000 description 1
- KAEGGIFPLJZUOZ-UHFFFAOYSA-N Renilla luciferin Chemical compound C1=CC(O)=CC=C1C(N1)=CN2C(=O)C(CC=3C=CC=CC=3)=NC2=C1CC1=CC=CC=C1 KAEGGIFPLJZUOZ-UHFFFAOYSA-N 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710149279 Small delta antigen Proteins 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229920000398 Thiolyte Polymers 0.000 description 1
- 102220615016 Transcription elongation regulator 1_S65C_mutation Human genes 0.000 description 1
- 102100034593 Tripartite motif-containing protein 26 Human genes 0.000 description 1
- APJYDQYYACXCRM-UHFFFAOYSA-N Tryptamine Natural products C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 1
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- MPFIISQEADXBEO-UHFFFAOYSA-M X-rhod-1 Chemical compound [Br-].CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C=2C3=CC=4CCCN5CCCC(C=45)=C3OC3=C4C5=[N+](CCC4)CCCC5=CC3=2)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O MPFIISQEADXBEO-UHFFFAOYSA-M 0.000 description 1
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
- APERIXFHHNDFQV-UHFFFAOYSA-N [2-[2-[2-[bis(carboxymethyl)amino]-5-methylphenoxy]ethoxy]-4-[3,6-bis(dimethylamino)xanthen-9-ylidene]cyclohexa-2,5-dien-1-ylidene]-bis(carboxymethyl)azanium;chloride Chemical compound [Cl-].C12=CC=C(N(C)C)C=C2OC2=CC(N(C)C)=CC=C2C1=C(C=1)C=CC(=[N+](CC(O)=O)CC(O)=O)C=1OCCOC1=CC(C)=CC=C1N(CC(O)=O)CC(O)=O APERIXFHHNDFQV-UHFFFAOYSA-N 0.000 description 1
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- RZUBARUFLYGOGC-MTHOTQAESA-L acid fuchsin Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=C(N)C(C)=CC(C(=C\2C=C(C(=[NH2+])C=C/2)S([O-])(=O)=O)\C=2C=C(C(N)=CC=2)S([O-])(=O)=O)=C1 RZUBARUFLYGOGC-MTHOTQAESA-L 0.000 description 1
- BGLGAKMTYHWWKW-UHFFFAOYSA-N acridine yellow Chemical compound [H+].[Cl-].CC1=C(N)C=C2N=C(C=C(C(C)=C3)N)C3=CC2=C1 BGLGAKMTYHWWKW-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- PWIGYBONXWGOQE-UHFFFAOYSA-N alizarin complexone Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=C(CN(CC(O)=O)CC(=O)O)C(O)=C2O PWIGYBONXWGOQE-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- JPIYZTWMUGTEHX-UHFFFAOYSA-N auramine O free base Chemical compound C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 JPIYZTWMUGTEHX-UHFFFAOYSA-N 0.000 description 1
- OJVABJMSSDUECT-UHFFFAOYSA-L berberin sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 OJVABJMSSDUECT-UHFFFAOYSA-L 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 108091006374 cAMP receptor proteins Proteins 0.000 description 1
- NMUGYJRMGWBCPU-UHFFFAOYSA-N calcium orange Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C(C(=C1)C([O-])=O)=CC=C1NC(=S)NC(C=1)=CC=C(N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)C=1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O NMUGYJRMGWBCPU-UHFFFAOYSA-N 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- NAXWWTPJXAIEJE-UHFFFAOYSA-N chembl1398678 Chemical compound C1=CC=CC2=C(O)C(N=NC3=CC=C(C=C3)C3=NC4=CC=C(C(=C4S3)S(O)(=O)=O)C)=CC(S(O)(=O)=O)=C21 NAXWWTPJXAIEJE-UHFFFAOYSA-N 0.000 description 1
- HQKOBNMULFASAN-UHFFFAOYSA-N chembl1991515 Chemical compound OC1=CC=C(Cl)C=C1N=NC1=C(O)C=CC2=CC=CC=C12 HQKOBNMULFASAN-UHFFFAOYSA-N 0.000 description 1
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229960001678 colestyramine Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- AFYCEAFSNDLKSX-UHFFFAOYSA-N coumarin 460 Chemical compound CC1=CC(=O)OC2=CC(N(CC)CC)=CC=C21 AFYCEAFSNDLKSX-UHFFFAOYSA-N 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- OOYIOIOOWUGAHD-UHFFFAOYSA-L disodium;2',4',5',7'-tetrabromo-4,5,6,7-tetrachloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 OOYIOIOOWUGAHD-UHFFFAOYSA-L 0.000 description 1
- BMAUDWDYKLUBPY-UHFFFAOYSA-L disodium;3-[[4-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-2-methylphenyl]diazenyl]naphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C=1C=C(N=NC=2C=C3C(=CC=CC3=C(C=2)S([O-])(=O)=O)S([O-])(=O)=O)C(C)=CC=1NC1=NC(Cl)=NC(Cl)=N1 BMAUDWDYKLUBPY-UHFFFAOYSA-L 0.000 description 1
- NPAWAMRXPHRVQY-WTVBWJGASA-L disodium;5-acetamido-2-[(e)-2-(4-isothiocyanato-2-sulfonatophenyl)ethenyl]benzenesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(NC(=O)C)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S([O-])(=O)=O NPAWAMRXPHRVQY-WTVBWJGASA-L 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 229910052876 emerald Inorganic materials 0.000 description 1
- 239000010976 emerald Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- NNMXSTWQJRPBJZ-UHFFFAOYSA-K europium(iii) chloride Chemical compound Cl[Eu](Cl)Cl NNMXSTWQJRPBJZ-UHFFFAOYSA-K 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 210000004164 leucophore Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- HYLDLLCHFLSKAG-UHFFFAOYSA-M lissamine flavine FF Chemical compound [Na+].C1=CC(C)=CC=C1N(C1=O)C(=O)C2=C3C1=CC=CC3=C(N)C(S([O-])(=O)=O)=C2 HYLDLLCHFLSKAG-UHFFFAOYSA-M 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-M lissamine rhodamine anion Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-M 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- MQDFABHLQLLJTE-BENRWUELSA-N methyl (2Z)-2-[3-(4-bromophenyl)-4-oxo-1,3-thiazolidin-2-ylidene]-2-cyanoacetate Chemical compound COC(=O)C(\C#N)=C1/SCC(=O)N1c1ccc(Br)cc1 MQDFABHLQLLJTE-BENRWUELSA-N 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- VWKNUUOGGLNRNZ-UHFFFAOYSA-N methylbimane Chemical compound CC1=C(C)C(=O)N2N1C(C)=C(C)C2=O VWKNUUOGGLNRNZ-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- FZTMEYOUQQFBJR-UHFFFAOYSA-M mitoTracker Orange Chemical compound [Cl-].C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC=C(CCl)C=C1 FZTMEYOUQQFBJR-UHFFFAOYSA-M 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- SUIPVTCEECPFIB-UHFFFAOYSA-N monochlorobimane Chemical compound ClCC1=C(C)C(=O)N2N1C(C)=C(C)C2=O SUIPVTCEECPFIB-UHFFFAOYSA-N 0.000 description 1
- MLEBFEHOJICQQS-UHFFFAOYSA-N monodansylcadaverine Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)NCCCCCN MLEBFEHOJICQQS-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- NMKIHZILXGGHHL-UHFFFAOYSA-N n,n'-bis[3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl]butane-1,4-diamine Chemical compound C1=C(OC)C=C2C(NCCCNCCCCNCCCNC3=C4C=CC(Cl)=CC4=NC4=CC=C(C=C43)OC)=C(C=CC(Cl)=C3)C3=NC2=C1 NMKIHZILXGGHHL-UHFFFAOYSA-N 0.000 description 1
- SHXOKQKTZJXHHR-UHFFFAOYSA-N n,n-diethyl-5-iminobenzo[a]phenoxazin-9-amine;hydrochloride Chemical compound [Cl-].C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=[NH2+])C2=C1 SHXOKQKTZJXHHR-UHFFFAOYSA-N 0.000 description 1
- VMCOQLKKSNQANE-UHFFFAOYSA-N n,n-dimethyl-4-[6-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-benzimidazol-2-yl]aniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 VMCOQLKKSNQANE-UHFFFAOYSA-N 0.000 description 1
- CSJXLKVNKAXFSI-UHFFFAOYSA-N n-(2-aminoethyl)-5-(dimethylamino)naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)NCCN CSJXLKVNKAXFSI-UHFFFAOYSA-N 0.000 description 1
- HSEVJGUFKSTHMH-UHFFFAOYSA-N n-(2-chloroethyl)-n-ethyl-3-methyl-4-[2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]aniline Chemical compound CC1=CC(N(CCCl)CC)=CC=C1C=CC1=[N+](C)C2=CC=CC=C2C1(C)C HSEVJGUFKSTHMH-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical class [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
- KUBDTFZQCYLLGC-VZORSVKHSA-N phallacidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KUBDTFZQCYLLGC-VZORSVKHSA-N 0.000 description 1
- NTGBUUXKGAZMSE-UHFFFAOYSA-N phenyl n-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(NC(=O)OC=3C=CC=CC=3)=CC=2)CC1 NTGBUUXKGAZMSE-UHFFFAOYSA-N 0.000 description 1
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920000889 poly(m-phenylene isophthalamide) Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- RSRNHSYYBLEMOI-UHFFFAOYSA-M primuline Chemical compound [Na+].S1C2=C(S([O-])(=O)=O)C(C)=CC=C2N=C1C(C=C1S2)=CC=C1N=C2C1=CC=C(N)C=C1 RSRNHSYYBLEMOI-UHFFFAOYSA-M 0.000 description 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- KXXXUIKPSVVSAW-UHFFFAOYSA-K pyranine Chemical compound [Na+].[Na+].[Na+].C1=C2C(O)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 KXXXUIKPSVVSAW-UHFFFAOYSA-K 0.000 description 1
- CXZRDVVUVDYSCQ-UHFFFAOYSA-M pyronin B Chemical compound [Cl-].C1=CC(=[N+](CC)CC)C=C2OC3=CC(N(CC)CC)=CC=C3C=C21 CXZRDVVUVDYSCQ-UHFFFAOYSA-M 0.000 description 1
- UKOBAUFLOGFCMV-UHFFFAOYSA-N quinacrine mustard Chemical compound C1=C(Cl)C=CC2=C(NC(C)CCCN(CCCl)CCCl)C3=CC(OC)=CC=C3N=C21 UKOBAUFLOGFCMV-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- XFKVYXCRNATCOO-UHFFFAOYSA-M rhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC=CC=C1C(=O)OCC XFKVYXCRNATCOO-UHFFFAOYSA-M 0.000 description 1
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 1
- 102200089551 rs5030826 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- DYPYMMHZGRPOCK-UHFFFAOYSA-N seminaphtharhodafluor Chemical compound O1C(=O)C2=CC=CC=C2C21C(C=CC=1C3=CC=C(O)C=1)=C3OC1=CC(N)=CC=C21 DYPYMMHZGRPOCK-UHFFFAOYSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- UGJCNRLBGKEGEH-UHFFFAOYSA-N sodium-binding benzofuran isophthalate Chemical compound COC1=CC=2C=C(C=3C(=CC(=CC=3)C(O)=O)C(O)=O)OC=2C=C1N(CCOCC1)CCOCCOCCN1C(C(=CC=1C=2)OC)=CC=1OC=2C1=CC=C(C(O)=O)C=C1C(O)=O UGJCNRLBGKEGEH-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000004758 synthetic textile Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- LQSATJAZEBYDQQ-UHFFFAOYSA-J tetrapotassium;2-[4-[bis(carboxylatomethyl)amino]-3-(carboxylatomethoxy)phenyl]-1h-indole-6-carboxylate Chemical compound [K+].[K+].[K+].[K+].C1=C(N(CC([O-])=O)CC([O-])=O)C(OCC(=O)[O-])=CC(C=2NC3=CC(=CC=C3C=2)C([O-])=O)=C1 LQSATJAZEBYDQQ-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- ACOJCCLIDPZYJC-UHFFFAOYSA-M thiazole orange Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1=CC=C2C(C=C3N(C4=CC=CC=C4S3)C)=CC=[N+](C)C2=C1 ACOJCCLIDPZYJC-UHFFFAOYSA-M 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XOSXWYQMOYSSKB-LDKJGXKFSA-L water blue Chemical compound CC1=CC(/C(\C(C=C2)=CC=C2NC(C=C2)=CC=C2S([O-])(=O)=O)=C(\C=C2)/C=C/C\2=N\C(C=C2)=CC=C2S([O-])(=O)=O)=CC(S(O)(=O)=O)=C1N.[Na+].[Na+] XOSXWYQMOYSSKB-LDKJGXKFSA-L 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502753—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/02—Adapting objects or devices to another
- B01L2200/026—Fluid interfacing between devices or objects, e.g. connectors, inlet details
- B01L2200/027—Fluid interfacing between devices or objects, e.g. connectors, inlet details for microfluidic devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0684—Venting, avoiding backpressure, avoid gas bubbles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/046—Function or devices integrated in the closure
- B01L2300/049—Valves integrated in closure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0864—Configuration of multiple channels and/or chambers in a single devices comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0481—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure squeezing of channels or chambers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
- B01L2400/049—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics vacuum
Definitions
- the present invention relates to an apparatus and a method for the detection, in particular for the determination of the concentration, of constituents in blood or water. Furthermore, the present invention relates to the use of a device or a method for the determination of constituents in blood. Finally, the invention relates to a kit comprising the device and a DNA standard.
- US 5,186,843 For example, a material for separating plasma or serum from blood is described.
- the material includes glass microfibers, cellulosic fibers and synthetic textile staple fibers. This medium is used to obtain small amounts of plasma that collect within the separation layer. However, the still necessary collection and further handling of the liquid for a quick and clean diagnosis hinder.
- US 4,816,224 describes a device for the separation of plasma or serum from whole blood, which can be designed differently. Glass fibers, which occupy a large volume, serve for separation.
- the device may comprise a plurality of filter layers.
- a device which allows the separation of plasma or serum from solid blood components by means of a filter membrane mounted in the device and pressure.
- the corresponding device may include a detection strip that allows the detection of components in the blood by immunochemical detection methods. However, these strips do not allow direct detection without further steps to be carried out by the staff and without the use of further auxiliaries or auxiliaries.
- the device is primarily intended for obtaining blood plasma or serum for further study.
- devices as described above are primarily used to provide small amounts of plasma or serum for further analysis.
- test strips only provide information on whether or not a substance is present within the detection capacity.
- these methods or devices are often not suitable because only accurate measurements of the concentration or content of a substance in a fluid, eg, blood, provide information about the exact condition of the patient and appropriate treatment methods.
- Further or additional objects of the present invention are the provision of a simple, safe and reliable device or method which allows, in particular, laypersons or non-medically trained personnel to provide a device which is simple and inexpensive to manufacture and / or store, and the provision of a corresponding kit.
- the present invention preferably relates to a device for detecting, in particular for determining the concentration, of constituents in blood, having a measuring range, a filter and at least one detection reagent for interacting with the constituents.
- detection of, for example, substances is meant in particular the determination of the presence or absence of a substance.
- the detection limit of the measuring method determines the result within the scope of the desired accuracy.
- fluids in blood is understood to mean, in particular, substances present in blood and / or dissolved substances.
- the substances may in particular be organic or inorganic or a mixture of both.
- components of other fluids can also be determined with the device of the present invention.
- Fluids are to be understood as liquids with solid constituents or suspensions.
- the fluid is a body fluid.
- Body fluids include, for example, blood, cerebrospinal fluid, urine, serous fluids, saliva, sperm, or abnormally altered stool.
- the fluid is water, in particular from lines, streams or lakes, etc.
- it can be determined, for example, whether a measured DNA correlates with the load on the water by microorganisms.
- a “measuring range” in the sense of the present invention is in particular a space, preferably with a defined or definable volume, in which at least one constituent of a fluid is determined. It is preferably at least partially transparent and particularly suitable for the determination of the substance or the constituent with preferably optical methods.
- the measuring range is preferably for z. B. visible light and the light of the emission wavelengths permeable.
- the filter in the present invention may include or include any material suitable for separation of blood or other solid-component fluids such exist.
- the filter may comprise, for example, polyethylene terephthalate (sold, for example, by Sekisui in a serum recovery product) or BTSSP (sold by Pall).
- the filter comprises glass fibers but is not completely made of glass fibers. Even more preferably, the volume or weight fraction of glass fibers is between 0% and 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20% or 10%, or between about 5% and 50% % of the filter, preferably between about 10% and 50%. Most preferred is a filter material without glass fibers. For filtering blood, the filter material should not cause hemolysis or bind analytes.
- the term "detection reagent” is used in particular to describe a substance with which the presence and / or concentration of another substance, preferably one in a fluid, eg. B. blood, plasma or water substance, detected or detected, understood.
- a detection reagent preferably has the property under certain conditions to enable or condition a detectable reaction.
- a detection reagent preferably interacts directly with the substance to be determined. It is either a covalent or a non-covalent bond with this substance.
- the detection reagent fluoresces reinforced only by binding to the analyte.
- the device according to the invention is preferably a ready-to-use or ready-to-use device which makes it possible to detect and in particular determine the concentration of the constituents in a simple and reliable manner without extensive preparatory measures.
- the present invention proves to be particularly advantageous in that a device is provided which is small, can be read with commercially available devices and / or the separation of the solid constituents of fluids, preferably from Blood, with the simultaneous measurement of components in the liquid phase connects. In this way, not only the centrifugation step is saved, which was previously necessary, for example, to separate solid blood components from the serum or plasma, but it is possible by simple and safe handling even untrained personnel, the analysis of fluids in the context of diagnostic procedures.
- the present device allows for the instantaneous measurement of the constituents of interest (ready-to-use) without further treatment and / or delay or other necessary measurement steps.
- the device has an opening for introducing a fluid, wherein the filter between the opening and measuring range is arranged.
- the device further comprises a fluid input region, which is preferably arranged between the opening and the measuring area, more preferably between the opening and the filter.
- the area between the opening and the measuring area and / or the fluid channel, preferably comprising the fluid input area is also summarized under the term filter area.
- the filter area preferably has a capacity of between about 200 and about 2000 ⁇ l. Depending on the fluid or, preferably, the amount and texture of the blood, up to 200 ⁇ l of plasma or serum can be obtained for measurement in the measuring range.
- the device according to the invention preferably allows the provision of a volume to be measured in the measurement range between about 15 ⁇ l and about 80 ⁇ l, preferably between about 20 ⁇ l and about 60 ⁇ l and most preferably about 40 ⁇ l serum or plasma.
- Pulsma is preferably understood to mean, in particular, the liquid phase of the blood which is separate from solid constituents such as cells (erythrocytes, white blood cells, etc.) and which can still coagulate.
- “Serum” is preferably understood to mean, in particular, the liquid fraction of the blood which is obtained after coagulation of the blood by separation of the cellular constituents mixed with platelets and coagulation factors to form the blood cake.
- each substance can be determined using suitable detection reagents.
- the ingredient to be detected or determined is a substance found in organisms.
- Organisms occurring substances may be organic or inorganic nature. Inorganic are, for example, minerals or mineral salts, trace elements, inorganic ions, metals and heavy metals, etc.
- Organic substances can belong to different substance classes.
- a group of substances form proteins, including enzymes. Enzymes convert their substrate into an end product. In the context of the present invention, preferably both the enzyme and the substrate and / or the end product can be determined. Also, non-enzyme proteins may preferably be detected or determined by the apparatus of the present invention.
- Other groups of organic substances include vitamins and coenzymes, nucleic acids, cytokines, hormones, histones, peptides, sugars, etc.
- nucleic acids comprising DNA and RNA in their single and / or double-stranded forms.
- the component to be detected or determined is a biological molecule selected from the group comprising DNA, RNA, proteins, hormones, cytokines.
- the latter substances may be free or associated be with other proteins.
- DNA in plasma or serum may also occur as a complex with histones and / or elastase as well as microsatellites.
- the component to be detected or to be determined is preferably the DNA / RNA of intact or intact bacteria, viruses and / or parasites from water samples contaminated with other particles. In this case, particles are retained by the filtration, while the nucleic acid contained in microorganisms can be made accessible to a measurement by suitable fluorescent dyes.
- the ingredient to be detected or determined is a drug.
- Drugs are substances which can be administered to an individual for controlling a pathological condition or disease. Drugs may also be the abovementioned biological molecules.
- DNA is determined or measured.
- the filter used in the present invention preferably binds little or no DNA.
- the bound fraction is preferably less than 30%, preferably less than 20%, most preferably less than 10% of the DNA contained in the fluid or blood.
- DNA can be detected in many ways. These include PCR as well as detection by detectable agents interacting specifically with DNA.
- the present invention preferably permits the determination of non-cell-bound DNA. Non-cell-bound DNA can be determined by different methods. In addition to the measurement of the fluorescence after addition of an intercalating dye, the measurement of the UV absorption of DNA is also used to determine the concentration. The sample volumes required for this have now reached the low ⁇ l range (eg measurement by NanoDrop in the range from 2 ⁇ l). The lower measurement limit for DNA is z. At about 10 ng / ml for the fluorescence method.
- ischemia / reperfusion disease After major operations, especially with heart-lung machine, but also after accidents with polytrauma, sepsis, burns and after ischemia / reperfusion disease (after arterial occlusion) there are strong, sometimes over-activations of the immune system.
- exemplary, but not exclusive, disease states are surgery, polytrauma, soft tissue trauma, ischemia / reperfusion disease, infarct, ischemia, embolism, infection, sepsis, transplantation, intoxication, eclampsia, drug side effects or transfusions. These can cause temporary or permanent damage in organs, but can also lead to death.
- the cellular component of this immune response is mediated by neutrophil granulocytes. To assess the consequences of activation, it is important to be up-to-date about the extent of the event.
- the present invention provides an apparatus and method for detecting the NETs that are already released within minutes of activation of the granulocytes producing them. Proofing in patient samples can lead to timely responses from the attending physicians who can save lives.
- More free DNA in the blood is released from dead cells. These cells may be dead by apoptotic or necrotic events.
- some therapies for example of cancer with chemo- or Radiotherapy induces apoptosis of cells, including blood cells. The therapeutic success can thus be detected directly and finely graded with the present invention.
- the presence and / or concentration of the component in the measuring range preferably depending on the detection reagent used, by means of luminescence, fluorescence, chemiluminescence, electrochemiluminescence, spectral absorption photometry, autofluorescence and / or bioluminescence determinable.
- the filter is adapted to separate solid components of the fluid flowing through the filter, and in particular to separate the solid and liquid phases of the fluid from each other.
- Some filter materials can be very brittle or fragile, so stabilization is necessary.
- it may contain an element for stabilization.
- Stabilizing elements are preferably stabilizing frames or frames or superimposed or integrated networks of a stable material, such as metal or plastic.
- the fluid input region, which is preferably encompassed by the filter region, of the device is designed such that an above ambient pressure is exerted on the fluid.
- the device is preferably designed such that such a pressure during the introduction of the fluid, preferably by a syringe or the like, is constructed.
- the device is designed such that the fluid is introduced under pressure through the filter in the measuring range.
- This pressure can preferably be exercised manually, for. B. by the piston of a syringe containing the unfiltered fluid to be measured.
- the device is a pressure lying below the ambient pressure, preferably a vacuum. If the sample to be determined is brought into contact with the device, causes the low pressure or the vacuum that the sample is passed or sucked without externally applied force in the device and inside the device, the solid components are separated from the fluid.
- the measuring range is preferably made of a preferably elastic material, which endeavors to assume a defined position or shape.
- the device is made of elastic material that is deformed such that the inner volume of the measuring chamber is smaller than that of the defined position, so that it unfolds eg when introducing the sample or the sample is sucked in during deployment.
- the measurement region is made of an inelastic material, wherein the region within the measurement region has a lower pressure than the ambient pressure before the sample enters the device.
- the detection reagent is provided in the measuring area or in a cavity / lumen located just before the measuring area, which preferably extends between the filter and the measuring area.
- the detection reagent is provided in the filter or in spatial proximity to the filter.
- the detection reagent interacts directly or indirectly with the constituent to be determined. Direct interaction is preferably in the case of the determination of DNA with reagents that attach to the DNA. In this case, the attachment can be covalent or noncovalent. Certain substances integrate into double-stranded and single-stranded DNA without covalent binding with the DNA (intercalators). In part, the substances only gain the property of fluorescence. By accumulation in the DNA and irradiation with light of certain wavelengths, these substances emit light of different wavelengths, which is quantitatively measurable and correlated with the amount of DNA. Fluorescent dyes may also be other than intercalators and be contacted by chemical modification with the DNA to be measured. In a further preferred embodiment, the detection reagent is selected from the group comprising Pico-Green TM, Alexa or Sytox® dyes, ethidium bromide and SYBR® dyes.
- a quantitative determination of a substance in the measuring range is carried out.
- the detection reagent when interacting with the target molecule, it is advantageous for the detection reagent, when interacting with the target molecule, to change its properties such that it becomes detectable.
- intercalators become detectable only upon incorporation into nucleic acids, whereas in the unbound state they do not exhibit this property.
- the detection reagent used in the present invention may already be detectable prior to interaction with the target molecule, but preferably alters its pertinent properties upon interaction with the target molecule. This is preferably done by shifting the absorption maximum or the emission wavelength of a detection reagent.
- the measurement of the non-cell-bound DNA preferably comprises the determination of the fluorescence emission after addition of a fluorescent dye to the plasma or serum.
- fluorophores can be used within the scope of the invention.
- suitable fluorophores 1.5 IAEDANS, 1,8-ANS, 4-methylumbelliferone, 4 ', 6-diamidino-2-phenylindole, 5- (and-6) -carboxy-2' , 7'-dichlorofluorescein pH 9.0, 5-carboxy-2,7-dichlorofluorescein, 5 carboxyfluorescein (5-FAM), 5-carboxynapthofluorescein (pH 10), 5-carboxytetramethylrhodamine (5-TAMRA), 5-FAM (5-carboxyfluorescein ), 5-FAM pH 9.0, 5-HAT (hydroxy tryptamine), 5-hydroxy tryptamine (HAT), 5-ROX (5-carboxy-X-rhodamine, triethylammonium salt), 5-ROX (carboxy-X-rhodamine) , 5-ROX pH 9.0, 5-HAT (hydroxy tryptamine),
- Particularly preferred here are 4 ', 6-diamidino-2-phenylindole, 7-AAD (7-aminoActinomycin D), acridine orange, DNA & RNA, acridine red, Alexa Fluor 594 TM, Alexa Fluor 610 R-Phycoerythrin streptavidin pH 7.2, Alexa Fluor 647 R-Phycoerythrin Streptavidin pH 7.2, Alexa Fluor 633 TM, Alexa Fluor 647 TM, Alexa Fluor 660 TM, Alexa Fluor 680 TM, Alexa Fluor 700, Alexa Fluor 750, allophycocyanin (APC), BOBO-3 DNA, BOBO TM -3, Bodipy 650/665-X, Cy5.5 TM , Cy5 TM , DAPI, DDAO, Draq5, ethidium bromide , Ethidium monoazide, ethidium homodimer, ethidium homodimer-1 (Eth
- Pico-Green TM and / or SYTOX Green are preferred.
- the dose of Pico-Green TM is preferably about 0.01 to 5 ⁇ l of reagent, preferably 0.05 to 2 ⁇ l, more preferably 0.1 to 0.5 ⁇ l of reagent, most preferably 0.15 to 0.3 ⁇ l Reagent per measurement at approx. 40 ⁇ l sample volume.
- the amount of reagent used is adjusted to the sample volume.
- the amount of solid in its content of detection reagent corresponds to the content of dissolved solid in o.g. Volumes.
- the opening of the device has a one-way valve.
- the opening has a Luer lock.
- the filter area is formed or delimited by a, preferably elastic, film.
- the film is preferably made of an artificial or natural polymer or mixed polymer.
- the device is a disposable device.
- the filter is designed to separate serum and / or plasma from the blood. In this case, preferably no lysis of the blood cells takes place, which can influence the measurement result.
- Such substances may be, for example, titanium dioxides or colestyramine.
- the device in particular with respect to their dimensions, compatible with commercially available detection devices.
- detection devices include, in particular, commercially available photometers, such as, for example, the Picofluor, TBS380 (Turner Biosystems, USA) or the qubit (Invitrogen, USA).
- the device and / or at least portions of the device to the dimensions of a commercially available cuvette and preferably has a diameter of about 10mm and / or a length of about 50 mm +/- 15 mm or by means of an adapter to the size of a commercially available cuvette customized.
- the device in particular for use with the qubit device, a cuvette in the form of a PCR tube (preferably with a use volume of 0.5 ml) on.
- the cuvette may be miniaturized, z. B. from a clear tube made of plastic or glass, with a filling volume of about 20-100 ul, a length of about 5-25mm and an inner diameter of about 1-4 mm.
- the device has at least one venting device.
- the venting takes place preferably by means of a narrow groove, a channel or a gap, preferably of a few mm length, which (r) opens into the measuring chamber or from this and the other end via a membrane of the outside air or environment is disconnected.
- This membrane is preferably a semi-permeable membrane which is permeable to air or gas but not aqueous fluid.
- the semipermeable membrane is particularly preferably attached to the lower end of the tube, preferably as a closure of the tube.
- the present apparatus provides an apparatus having an integrated automatic size measurement chamber.
- the measuring range preferably connects in the filling direction or flow direction of the fluid behind the filter and fills due to the design, arrangement and vent preferably free of air bubbles with filtrate or filtered fluid. This is preferably done in a precisely determinable and correct amount, suitable or matched to the amount of Detektionsreagenz so that after filling to the semipermeable membrane no further flow can take place.
- the volume is determined by the volumes of the fluid spaces in the cuvette part.
- the present invention thus allows, in particular, an automatic quantity measurement or quantity predetermination with the advantage that in particular pipetting or other fluid handling is not necessary.
- the measuring region can also already be partially prefilled, wherein this prefilling can have a dilution buffer with a detection reagent.
- the remaining fillable volume of the measuring range can then be filled with a quantity of filtered fluid limited by the residual volume and thus defined and can be measured after a short incubation time in a fluorescence photometer. After balancing the measured value thus obtained with a standard taking into account one blank value (or blanks), the amount of a substance that is contained in the fluid can be determined.
- the venting device is connected to the measuring chamber by a narrow groove or a gap, which is arranged opposite to the inlet opening of the measuring chamber.
- the measuring range is in the form of a conventional (PCR) tube, more preferably with a ventilation device, before or is designed as such, on which the remaining device is attached.
- PCR PCR
- the device preferably has at least one second measuring range. This enables the simultaneous determination of several measured values or the simultaneous determination of one or more calibration values. Preferably, the device has at least one further measuring range for providing a blank or calibration value.
- the component to be determined interacts with two detection reagents.
- the detection or the concentration determination is carried out with two detection reagents in a two-step reaction.
- the first binding detection reagent interacts specifically with the constituent to be determined.
- This first reagent is preferably coupled to a detectable substance.
- the detectable substance preferably corresponds to one of the above-mentioned fluorescent dyes.
- the second detection reagent is immobilized to a certain area in the measurement area.
- the first detection reagent is preferably located in the device in an area in front of the measuring area, for example in a fluid channel, filter area or in a mixing chamber leading thereto.
- the blood or the separated plasma or serum should come into contact with the first detection reagent, so that the latter can bind to the substance to be determined.
- the complex of the substance to be determined and the first detection reagent then passes with the plasma or serum into the measurement area, where it binds to a second detection reagent which is in a certain range of the measurement range is immobilized. By accumulating the complex at this point, the constituent to be determined becomes detectable. Excess first detection reagent remains evenly distributed in serum or plasma.
- a control value can be determined which reflects the concentration of the first detection reagent distributed throughout the solution.
- This control value can also be programmed as a threshold or limit value into a suitable measuring instrument via software.
- both reagents added for the detection are regarded as detection reagents, whereby the first detection reagent does not have to change its property of detectability upon binding of the constituent to be determined, as described above. However, it is preferred that the first detection reagent has this property.
- Both detection reagents bind directly to the component to be determined, so that the actual detection or determination of the component by detection of the first detection reagent, while the second detection reagent fixes the antigen at a position and this position after enrichment as a result of a finite flow with antigen-containing Liquid is supplied to a photo-optical measurement.
- the detection reagents are preferably antibodies or antibody fragments.
- the antibody is coupled to a substance to be detected.
- a substance to be detected for example, R-phycoerythrin (PE), fluorescein isothiocyanate (FITC), PE-Cy5 allophycocyanin (APC), PE-Texas Red TM , Peridinin Chlorophyll Protein (PerCP), PerCP-Cy5.5, APC-Cy7, and / or Texas Red TM , etc.
- Components to be determined in a two-step reaction are, for example, endogenous substances such as interleukin 6 (IL-6), hemoglobin, bilirubin, CRP, lactoferrin, procalcitonin, AT-III, protein C, p24 (HIV) or antibodies. Even foreign substances such as viruses, bacteria, drugs, toxins, drugs or fragments of the substances mentioned can thus be determined.
- endogenous substances such as interleukin 6 (IL-6), hemoglobin, bilirubin, CRP, lactoferrin, procalcitonin, AT-III, protein C, p24 (HIV) or antibodies.
- the device according to the invention thus enables the qualitative and / or quantitative determination of a blood component, in particular without further, manual or laboratory work steps.
- the present invention also relates to a method for detecting, in particular, for determining the concentration of constituents in blood, preferably using a device of the present invention.
- the method comprises the steps of (a) providing a device comprising a measurement region, a filter and a detection reagent, (b) introducing a fluid into the device, and (c) detecting the concentration of the component using the device.
- the step of detecting the concentration of the component is preferably carried out using a conventional measuring device, preferably a fluorescence photometer.
- the present invention also relates to the use of a device or method of the present invention for determining constituents in blood, such as, bilirubin, free hemoglobin, IL-6 or p24 (HIV protein), CRP. Further preferred is the use for the determination of cell-free DNA. Hemoglobin or bilirubin is preferably measured by measuring the photoabsorption using appropriate wavelengths or by measuring the intrinsic characteristic fluorescence of these substances.
- the present invention further relates to a kit comprising at least one device according to the present invention, and a (fluorescence) standard of e.g. B. may contain DNA.
- the kit preferably further comprises a syringe, preferably with accessories for taking blood from a patient, and / or a measuring device.
- the kit preferably comprises a manual with interpretation aids.
- the measuring device may further comprise a device, which is particularly suitable for measuring the samples which were produced with the device. This may include software that allows storage and management of the data. This may include an adapter cable. It may further include a battery pack that allows off-grid measurements.
- the inventive device such as in FIG. 1 and 8th is used to detect and preferably determine the concentration of constituents in fluids.
- the fluid is blood and the component to be determined is DNA.
- the device after Fig. 1-7 comprises a measuring region 3 and a filter region 5 in fluid communication with the latter.
- the filter region 5 and the measuring region 3 are preferably connected to one another via a first fluid channel 7.
- the device 1 preferably further comprises an opening 9, which is preferably designed as a Luer-lock and further preferably with a one-way valve.
- the opening 9 is preferably located directly at the fluid inlet region of the filter region 5 or is connected thereto via a tube 11, preferably comprising a polymer, preferably of polyvinyl chloride (PVC) or polyethylene (PE).
- PVC polyvinyl chloride
- PE polyethylene
- the filter region 5 is preferably elastic and bag-like and further or additionally preferably made of soft PVC, PE, a mixed or composite polymer.
- the opening 9 is preferably formed, for example by training as Luer-Lock, that a commercial syringe (not shown) can be connected to it.
- a such syringe filled fluid, in particular blood introduced via the opening 9 and optionally the tube 11 in the filter area 5.
- the filter region 5 is preferably designed such that it experiences a predetermined expansion when introducing a certain amount or a certain volume of fluid, which in turn causes a certain pressure on the interior of the filter region 5. Materials to be introduced or required volume and the like are preferably coordinated accordingly.
- the formation of the opening 9 with a one-way valve prevents the escape of the pressurized, in the fluid input area of the or filter area (s) 5 existing fluid.
- the fluid contained in it is forced through a filter, preferably a special membrane, which is furthermore preferably welded into the filter region 5.
- the filter area 5 preferably has an outlet which opens into the fluid channel 7, which in turn leads to the measuring area 3.
- the filter is preferably arranged in such a way that the pressurized fluid present in the filter region 5 is transported through the filter (not shown) into the fluid channel 7 and thus into the measuring region 3.
- the fluid thus filtered preferably the blood plasma, and in particular preferably a predetermined volume of blood plasma, is thus provided in the measuring chamber 3.
- the apparatus further comprises a detection reagent, preferably Pico-Green TM , which is provided in the measuring chamber 3 and / or in the fluid channel 7 in such a way that it collects with the blood plasma or serum flowing through the fluid channel and / or with that collected in the measuring chamber 3 Blood plasma or serum comes into contact and in particular interacts, preferably such that a detection, in particular a determination of the concentration of constituents in the fluid or blood plasma, is made possible.
- a detection reagent preferably Pico-Green TM
- the device and in particular the volumes of measuring area 3, filter area 5 and fluid channel 7 (respectively part 17) and the properties of the filter area 5 with respect to elasticity and pressure build-up and the filter with respect to the filter and passage properties are coordinated such that in the measuring chamber. 3 or in the fluid channel 7 (or part 17) a predetermined amount of blood plasma is present, which interacts with a predetermined amount of detection reagent.
- the measuring chamber 3 and / or the fluid channel 7 (or part 17) is preferably coated on its interior area communicating with the blood plasma, at least partially with a detection reagent, which preferably contains or consists of Pico-Green TM or SytoxGreen. Furthermore, a rapidly dissolvable pellet which has a detection reagent can also be positioned in the region of the measuring chamber 3 or the fluid channel 7 (or part 17).
- a channel descends from the measuring area 3.
- a channel preferably opens into a vent opening or vent recess or recess 15, which is preferably arranged in the outer region of the device and is sealed with a semi-permeable membrane (not shown) from the environment.
- a semi-permeable membrane (not shown) from the environment.
- a membrane preferably has the property that, seen from the inside of the device, it is permeable to air or gaseous media, but not to liquid media or blood plasma.
- the channel and the venting area 15 are designed to discharge excess air present outwardly into the environment when filling the filter area 5 or the fluid channel 7 and the measuring area 3 in the device 1, in other words to vent the device 1. This advantageously allows, in particular, the introduction of a defined volume of liquid into the measuring area.
- the device 1 thus allows automatic filling of the measuring region 3 with a defined amount of blood plasma and mixing with a detection reagent.
- the device and the fluid present in the measuring range preferably blood plasma, are accessible in particular to a photo-optical detection.
- a photo-optical detection As described above, for example, for the purpose of detecting free DNA by means of an intercalating fluorescent dye such as Pico-Green TM .
- the detection reagent is preferably applied to the inside of the measuring chamber 5 or the measuring channel, preferably via ink jet, and dried. Alternatively or additionally, the detection reagent is present as dust or pellet present in the measuring chamber or, for example, within the inflow channel as easily soluble material.
- the device preferably has a diameter of about 10 mm and a length or height of about 50 mm +/- 15 mm.
- the measuring area is preferably at least partially transparent or translucent, in particular in order to ensure an optical detection of the component to be detected or determined, preferably by means of a fluorescence measurement.
- FIGS. 2 to 6 or 7
- FIGS. 2 to 4 Devices that are basically related to the design and operation of FIG. 1
- these devices have a plurality of measuring regions 3, and preferably 2 or 3 measuring regions, wherein these measuring regions can be arranged differently.
- the general structure and the operation is on the above description of FIG. 1 directed.
- Ventilation channels 13 and vent areas 15 are adapted to perform several parallel measurements, or evidence or determinations, each of the measuring ranges 3 and / or fluid channels 7 may have the same or different detection reagents.
- At least one of the measuring ranges is provided for determining a blank value.
- a blank or zero value is a value used to compare the sample to be measured.
- blood plasma filtered as a blank can be measured without reagent in the blank measurement range, which then indicates approximately autofluorescence.
- a calibration value can be formed, preferably with the measurement of a fluid of the same type, which is mixed with standardized amounts of the substance to be measured. More preferably, a calibration value can be formed by measuring a cuvette, which is filled, for example, with a fluid that is optically similar to the blood plasma or else a plastic and has a stable, defined fluorescence. Based on these values, the corresponding measured value of the sample (s) is evaluated. So you can z. B. make a standard daily measurement and make each of the patient a blank and a reading of the analyte of interest.
- the corresponding preferred embodiments thus allow the simultaneous performance of parallel, identical measurements or parallel different measurements.
- the preferred embodiments also have the same design as in FIGS. 2 to 6 (or 7), the volumes of measuring range 3, filter area 5 and fluid channels 7 and the properties of the Filter range 5 in terms of elasticity and pressure build-up and the filter with respect to the filter and passage properties matched to one another such that in the measuring chambers 3 and in the fluid channels 7, a predetermined amount of blood plasma is present, which interacts with a predetermined amount of Detektionsreagenz (ien).
- FIG. 5 again shows a preferred embodiment according to the invention of a device having a measuring chamber, wherein only a modified, flow-optimized measuring region 3 (see FIG FIG. 5a, FIG. 5 ) is shown.
- a modified, flow-optimized measuring region 3 see FIG FIG. 5a, FIG. 5 .
- FIG. 6 shows a further preferred embodiment of a device according to the invention according to a mixing chamber 25, in which there is preferably a reagent which binds to the / to be measured component (s), a further chamber 20 is arranged downstream.
- a detection reagent for example an antibody, is firmly bound to a substrate which preferably at least partially contains silicon dioxide (eg glass) or polystyrene or polyurethane.
- a component to be measured for example an antigen
- a component to be measured then combines in the filter region 5, mixing chamber 25 and / or the channel 7 with a first detection reagent, for example a fluorescence-labeled antibody, and on further flow in the chamber 20 by another to the substrate bound antibody to the substrate and thus determines the presence of the antigen and / or its concentration by fluorescence photometric measurement of the chamber 20.
- a first detection reagent for example a fluorescence-labeled antibody
- Both detection reagents can bind to different regions of the component to be determined, in the case of antibodies to different epitopes of the antigen.
- FIG. 7 shows a schematic view of a preferred device according to the invention with a disc-shaped filter 16.
- Fig. 7a shows a schematic plan view of the device and
- Fig. 7b a schematic View of the device according to Fig. 7a from above from above Fig. 7a , The remaining arrangement shown corresponds to those already described.
- FIG. 8 shows a schematic plan view of a preferred embodiment of a device according to the invention with a tube-like cuvette 17, which has a z. B. may contain pelleted, readily soluble reagent 23.
- This device according to the invention also allows automatic filling of the measuring range with a defined amount of blood plasma and mixing with a detection reagent.
- the part 17 is preferably provided with a semi-permeable membrane 15 as a closure.
- the device and the fluid present in the measuring range, preferably blood plasma, are accessible in particular to a photo-optical detection.
- the tube-like, translucent measuring cuvette has a length of about 20 mm, an inner diameter of about 1-4 mm and an outer diameter of about 2-6 mm;
- FIG. 9 shows a schematic plan view of a preferred embodiment according to the invention of a device in a variant with two tube-like cuvettes 17, in which one can be provided with detection reagent while the other can be measured without reagent, a blank or blank,
- FIG. 10 shows a schematic plan view of a preferred embodiment according to the invention of a device in a variant with a mixing chamber 20 which may contain a reagent, wherein the reagent in the chamber 20 particularly advantageously mixes with the filtrate.
- FIG. 11 shows a schematic plan view of a preferred embodiment according to the invention of a device in a variant which allows the automatic filling of the measuring range with a defined amount of previously prepared by conventional methods blood plasma.
- the tube or tube-like The cuvette has a length of approximately 20 mm and an outer diameter of approximately 2-6 mm and may contain a reagent in the region 19.
- the present invention thus provides an advantageous apparatus, methods and kit that overcomes the disadvantages of the prior art.
- the present invention allows separation of plasma or serum from whole blood and analysis of serum or plasma without the need for centrifugation or similar laboratory processing steps of the recovered serum or plasma.
- the present invention provides a device, a method and a kit that are easy to handle, safe and reliable, and are particularly suitable for use by laymen or non-medically trained personnel as well as simple and inexpensive to manufacture to perform and / or store.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
Die vorliegende Erfindung betrifft eine Vorrichtung und ein Verfahren zum Nachweis, insbesondere zur Bestimmung der Konzentration, von Bestandteilen in Blut oder Wasser. Weiterhin betrifft die vorliegende Erfindung die Verwendung einer Vorrichtung bzw. eines Verfahrens zur Bestimmung von Bestandteilen in Blut. Schließlich bezieht sich die Erfindung auf einen Kit, umfassend die Vorrichtung und einen DNA-Standard.The present invention relates to an apparatus and a method for the detection, in particular for the determination of the concentration, of constituents in blood or water. Furthermore, the present invention relates to the use of a device or a method for the determination of constituents in blood. Finally, the invention relates to a kit comprising the device and a DNA standard.
Nachfolgend wird eine Reihe von Dokumenten zitiert. Der Inhalt dieser Dokumente inklusive Bedienungsanleitungen ist hiermit in seiner Gesamtheit durch Referenz inkorporiert.Below is a series of documents cited. The contents of these documents including operating instructions are hereby incorporated in their entirety by reference.
Verfahren zur medizinischen Diagnose werden routinemäßig verwendet, um anhand der Bestimmung der Anwesenheit und/oder der Konzentration von im Blut gelösten Stoffen den klinischen Status von Patienten abschätzen zu können. Bislang müssen Analysen des Blutplasmas und/oder Serums mit einem Zentrifugationsschritt durchgeführt werden, damit das zu analysierende Blutplasma von den festen Blutbestandteilen getrennt werden kann. Offensichtlich existieren keine geeigneten alternativen Verfahren oder eine Vorrichtung zur Abtrennung der festen Blutbestandteile. Zentrifugation ist nicht nur zeitaufwändig, sondern stellt gerade auch in Entwicklungsgebieten eine große Hürde dar, weil dort oftmals nicht nur Mangel an geeigneten Zentrifugen sondern auch am Strom zu deren Betreibung herrscht. Außerdem gibt es in vielen Gebieten der Erde oftmals kein Fachpersonal, das ohne weiteres Blutanalysen mit bekannten Mitteln durchführen könnte.Medical diagnostic procedures are routinely used to estimate the clinical status of patients by determining the presence and / or concentration of solutes in the blood. So far, analyzes of the blood plasma and / or serum must be performed with a centrifugation step so that the blood plasma to be analyzed can be separated from the solid blood components. Obviously, there are no suitable alternative methods or apparatus for separating the solid blood components. Centrifugation is not only time-consuming, but also represents a major hurdle, especially in development areas, because there is often not only a shortage of suitable centrifuges but also the power to operate them. In addition, in many areas of the world, there is often no skilled person who could easily carry out blood analyzes by known means.
Es besteht daher Bedarf an einer Vorrichtung bzw. einem Verfahren, die/das die Analyse von in Blutplasma und/oder Serum befindlichen Stoffen insbesondere ohne Zentrifugation ermöglicht. Überdies sollte eine entsprechende Vorrichtung oder ein Verfahren auch ungeübtem Personal ohne zeitaufwändige Einarbeitung den schnellen, sauberen und richtigen Umgang mit solchen Analysen ermöglichen.There is therefore a need for a device or a method which allows the analysis of substances located in blood plasma and / or serum, in particular without centrifugation. Moreover, a corresponding device or a Procedures allow even untrained personnel without time-consuming training to enable the fast, clean and correct handling of such analyzes.
In
In
In
Vorrichtungen wie oben beschrieben dienen also hauptsächlich zur Bereitstellung geringer Mengen von Plasma oder Serum für weitere Analysen.Thus, devices as described above are primarily used to provide small amounts of plasma or serum for further analysis.
Mit vorhandenen Verfahren und Vorrichtungen zur Untersuchung von Plasma oder Serum und/oder anderer Körperflüssigkeiten, die auf den schnellen Erhalt eines Messergebnisses ausgelegt sind, können oftmals nur Richtwerte erhalten werden und nicht selten nur Aussagen über das Vorhandensein oder die Abwesenheit von zu messenden Bestandteilen einer Flüssigkeit gemacht werden. So geben beispielsweise Teststreifen nur Auskunft darüber, ob ein Stoff im Rahmen der Nachweiskapazität vorhanden ist oder nicht. Im Rahmen der Diagnose bestimmter Krankheiten und/oder Zustände in Proben aus Patienten sind diese Verfahren bzw. Vorrichtungen jedoch oftmals nicht geeignet, da nur genaue Messwerte über die Konzentration oder den Gehalt eines Stoffes in einem Fluid, z.B. Blut, Aufschluss geben über den genauen Zustand des Patienten und geeignete Behandlungsmethoden.With existing methods and devices for the examination of plasma or serum and / or other body fluids, which are designed to quickly obtain a measurement result, often only indicative values can be obtained, and often only statements about the presence or absence of constituents of a liquid to be measured be made. So give For example, test strips only provide information on whether or not a substance is present within the detection capacity. However, in the context of the diagnosis of certain diseases and / or conditions in samples from patients, these methods or devices are often not suitable because only accurate measurements of the concentration or content of a substance in a fluid, eg, blood, provide information about the exact condition of the patient and appropriate treatment methods.
Es ist somit eine der Erfindung zugrunde liegende Aufgabe, eine Vorrichtung und ein Verfahren bereitzustellen, die die Nachteile des Standes der Technik überwinden. Insbesondere ist es eine Aufgabe, eine Vorrichtung bereitzustellen, mittels derer die Trennung von Plasma oder Serum von Vollblut und eine Analyse von im Serum oder Plasma befindlichen Stoffen durchgeführt werden kann, ohne dass Zentrifugationsschritte oder ähnliche labortechnische Verarbeitungsschritte des gewonnenen Serums oder Plasmas notwendig sind. Weitere oder zusätzliche Aufgaben der vorliegenden Erfindung sind die Bereitstellung einer einfach, sicher und zuverlässig zu handhabenden Vorrichtung bzw. eines einfach durchzuführenden Verfahrens, das insbesondere eine Verwendung bzw. Durchführung durch Laien bzw. nicht medizinisch geschultes Personal erlaubt, das Bereitstellen einer Vorrichtung, die einfach und kostengünstig herzustellen und/oder zu Lagern ist, sowie die Bereitstellung eines entsprechenden Kits.It is therefore an object underlying the invention to provide an apparatus and a method which overcomes the disadvantages of the prior art. In particular, it is an object to provide a device by means of which the separation of plasma or serum from whole blood and an analysis of serum or plasma substances can be carried out without centrifugation steps or similar laboratory processing steps of the recovered serum or plasma are necessary. Further or additional objects of the present invention are the provision of a simple, safe and reliable device or method which allows, in particular, laypersons or non-medically trained personnel to provide a device which is simple and inexpensive to manufacture and / or store, and the provision of a corresponding kit.
Diese Aufgabe wird durch die in den Ansprüchen definierten Merkmale gelöst.This object is achieved by the features defined in the claims.
Die vorliegende Erfindung bezieht sich vorzugsweise auf eine Vorrichtung zum Nachweis, insbesondere zur Bestimmung der Konzentration, von Bestandteilen in Blut, aufweisend einen Messbereich, ein Filter sowie mindestens ein Detektionsreagenz zum Wechselwirken mit den Bestandteilen.The present invention preferably relates to a device for detecting, in particular for determining the concentration, of constituents in blood, having a measuring range, a filter and at least one detection reagent for interacting with the constituents.
Im Falle einer Messung von Autofluoreszenz oder Absorption von Fluidbestandteilen kann auch auf ein Detektionreagenz verzichtet werden.In the case of a measurement of autofluorescence or absorption of fluid constituents, it is also possible to dispense with a detection reagent.
Unter "Nachweis" von beispielsweise Stoffen versteht man insbesondere die Feststellung der An- oder Abwesenheit eines Stoffes. Dabei legt die Nachweisgrenze des Messverfahrens im Rahmen der erwünschten Genauigkeit das Ergebnis fest.By "detection" of, for example, substances is meant in particular the determination of the presence or absence of a substance. The detection limit of the measuring method determines the result within the scope of the desired accuracy.
Die "Konzentration" von Stoffen ist, insbesondere im Gegensatz zur absoluten Stoffmenge, volumenunabhängig.The "concentration" of substances, especially in contrast to the absolute amount of substance, volume-independent.
Unter "Bestandteilen in Blut" versteht man im Rahmen der vorliegenden Erfindung insbesondere in Blut vorhandene und/oder gelöste Stoffe. Die Stoffe können insbesondere organisch oder anorganisch oder eine Mischung aus beidem sein. Grundsätzlich lassen sich mit der Vorrichtung der vorliegenden Erfindung auch Bestandteile aus anderen Fluiden bestimmen. Fluide sind hier als Flüssigkeiten mit festen Bestandteilen oder Supensionen zu verstehen. Vorzugsweise ist das Fluid eine Körperflüssigkeit. Körperflüssigkeiten sind zum Beispiel Blut, Liquor, Urin, seröse Flüssigkeiten, Speichel, Sperma oder krankhaft veränderter Stuhl.
Vorzugsweise ist das Fluid Wasser, insbesondere aus Leitungen, Bächen oder Seen etc. Hier kann beispielsweise bestimmt werden, ob eine gemessene DNA mit der Belastung des Wassers durch Mikroorganismen korreliert.In the context of the present invention, "constituents in blood" is understood to mean, in particular, substances present in blood and / or dissolved substances. The substances may in particular be organic or inorganic or a mixture of both. In principle, components of other fluids can also be determined with the device of the present invention. Fluids are to be understood as liquids with solid constituents or suspensions. Preferably, the fluid is a body fluid. Body fluids include, for example, blood, cerebrospinal fluid, urine, serous fluids, saliva, sperm, or abnormally altered stool.
Preferably, the fluid is water, in particular from lines, streams or lakes, etc. Here it can be determined, for example, whether a measured DNA correlates with the load on the water by microorganisms.
Ein "Messbereich" im Sinne der vorliegenden Erfindung ist insbesondere ein Raum, vorzugsweise mit einem definierten oder definierbaren Volumen, in dem mindestens ein Bestandteil eines Fluids bestimmt wird. Er ist vorzugsweise zumindest teilweise transparent und insbesondere für die Bestimmung der Substanz beziehungsweise des Bestandteils mit vorzugsweise optischen Verfahren geeignet.A "measuring range" in the sense of the present invention is in particular a space, preferably with a defined or definable volume, in which at least one constituent of a fluid is determined. It is preferably at least partially transparent and particularly suitable for the determination of the substance or the constituent with preferably optical methods.
Zur Verwendung mit bevorzugten Detektionsreagenzien, die bspw. durch Licht bestimmter Wellenlängenbereiche angeregt werden und Licht von bestimmten Wellenlängebereichen emittieren, ist der Messbereich vorzugsweise für z. B. sichtbares Licht sowie das Licht der Emissionswellenlängen durchlässig.For use with preferred detection reagents, which are excited, for example, by light of certain wavelength ranges and emit light of certain wavelength ranges, the measuring range is preferably for z. B. visible light and the light of the emission wavelengths permeable.
Das Filter in der vorliegenden Erfindung kann jedes zur Auftrennung von Blut oder anderen Fluiden mit festen Bestandteilen geeignete Material umfassen oder aus einem solchen bestehen. Das Filter kann zum Beispiel Polyethyleneterephthalat (vertrieben beispielsweise durch die Firma Sekisui in einem Produkt zur Gewinnung von Serum) oder BTSSP (vertrieben durch die Firma Pall) umfassen.The filter in the present invention may include or include any material suitable for separation of blood or other solid-component fluids such exist. The filter may comprise, for example, polyethylene terephthalate (sold, for example, by Sekisui in a serum recovery product) or BTSSP (sold by Pall).
Bereits bekannte geeignete Filter und/oder Filtermaterialien sind z. B. in
Vorzugsweise umfasst das Filter Glasfasern, besteht jedoch nicht vollständig aus Glasfasern. Noch weiter bevorzugt liegt der Volumen- oder Gewichtsanteil an Glasfasern zwischen 0% und 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20% oder 10% oder er liegt zwischen etwa 5% und 50% des Filters, bevorzugt zwischen etwa 10% und 50%. Am meisten bevorzugt ist ein Filtermaterial ohne Glasfasern. Für die Filtrierung von Blut sollte das Filtermaterial keine Hämolyse verursachen sowie keine Analyten binden.Preferably, the filter comprises glass fibers but is not completely made of glass fibers. Even more preferably, the volume or weight fraction of glass fibers is between 0% and 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20% or 10%, or between about 5% and 50% % of the filter, preferably between about 10% and 50%. Most preferred is a filter material without glass fibers. For filtering blood, the filter material should not cause hemolysis or bind analytes.
Unter "Detektionsreagenz" im Rahmen der vorliegenden Erfindung wird insbesondere eine Substanz, mit der die Anwesenheit und/oder die Konzentration einer anderen Substanz, bevorzugt einer in einem Fluid, z. B. Blut, Plasma oder Wasser befindlichen Substanz, nachgewiesen oder detektiert werden kann, verstanden. Dabei weist ein Detektionsreagenz vorzugsweise die Eigenschaft auf, unter bestimmten Bedingungen eine detektierbare Reaktion zu ermöglichen oder zu bedingen. Ein Detektionsreagenz interagiert vorzugsweise direkt mit der zu bestimmenden Substanz. Dabei geht es entweder eine kovalente oder eine nichtkovalente Bindung mit dieser Substanz ein. Bevorzugt fluoresziert das Detektionsreagenz verstärkt erst durch die Bindung an das Analyt.In the context of the present invention, the term "detection reagent" is used in particular to describe a substance with which the presence and / or concentration of another substance, preferably one in a fluid, eg. B. blood, plasma or water substance, detected or detected, understood. In this case, a detection reagent preferably has the property under certain conditions to enable or condition a detectable reaction. A detection reagent preferably interacts directly with the substance to be determined. It is either a covalent or a non-covalent bond with this substance. Preferably, the detection reagent fluoresces reinforced only by binding to the analyte.
Die erfindungsgemäße Vorrichtung ist vorzugsweise eine gebrauchsfertige oder ready-to-use Vorrichtung, die den Nachweis und insbesondere Bestimmung der Konzentration der Bestandteile auf einfache und zuverlässige Weise ohne umfangreiche vorbereitende Maßnahmen ermöglicht. Die vorliegende Erfindung erweist sich insbesondere dahingehend als vorteilhaft, dass eine Vorrichtung bereitgestellt wird, die klein ist, mit handelsüblichen Geräten ausgelesen werden kann und/oder die Trennung der festen Bestandteile aus Fluiden, vorzugsweise aus Blut, mit der gleichzeitigen Messung von in der flüssigen Phase befindlichen Bestandteilen verbindet. Auf diese Weise wird nicht nur der Zentrifugationsschritt eingespart, der bislang notwendig war, um z.B. feste Blutbestandteile vom Serum oder Plasma abzutrennen, sondern es wird durch einfache und sichere Handhabung auch ungeübtem Personal die Analyse von Fluiden im Rahmen von diagnostischen Verfahren ermöglicht. Ein weiterer Vorteil ist die nun mögliche genaue Bestimmung der Konzentration von Bestandteilen beispielsweise zur Abschätzung des Zustandes von Patienten nach Operationen oder bei bestimmten Krankheitszuständen. Schließlich ermöglicht die vorliegende Vorrichtung die sofortige Messung der interessierenden Bestandteile (ready-to-use) ohne weitere Behandlung und/oder Verzögerung oder weitere notwendige Messschritte.The device according to the invention is preferably a ready-to-use or ready-to-use device which makes it possible to detect and in particular determine the concentration of the constituents in a simple and reliable manner without extensive preparatory measures. The present invention proves to be particularly advantageous in that a device is provided which is small, can be read with commercially available devices and / or the separation of the solid constituents of fluids, preferably from Blood, with the simultaneous measurement of components in the liquid phase connects. In this way, not only the centrifugation step is saved, which was previously necessary, for example, to separate solid blood components from the serum or plasma, but it is possible by simple and safe handling even untrained personnel, the analysis of fluids in the context of diagnostic procedures. Another advantage is the now possible accurate determination of the concentration of components, for example, to estimate the condition of patients after surgery or in certain disease states. Finally, the present device allows for the instantaneous measurement of the constituents of interest (ready-to-use) without further treatment and / or delay or other necessary measurement steps.
Vorzugsweise weist die Vorrichtung eine Öffnung zum Einbringen eines Fluids auf, wobei das Filter zwischen Öffnung und Messbereich angeordnet ist.Preferably, the device has an opening for introducing a fluid, wherein the filter between the opening and measuring range is arranged.
Vorzugsweise weist die Vorrichtung ferner einen Fluideingangsbereich auf, der vorzugsweise zwischen der Öffnung und dem Messbereich, weiter bevorzugt zwischen Öffnung und Filter angeordnet ist.Preferably, the device further comprises a fluid input region, which is preferably arranged between the opening and the measuring area, more preferably between the opening and the filter.
Im folgenden wird der Bereich zwischen der Öffnung und dem Messbereich und/oder dem Fluidkanal, vorzugsweise umfassend den Fluideingangsbereich, auch unter dem Begriff Filterbereich zusammengefasst.In the following, the area between the opening and the measuring area and / or the fluid channel, preferably comprising the fluid input area, is also summarized under the term filter area.
Der Filterbereich hat vorzugsweise ein Fassungsvermögen von zwischen ca. 200 und ca. 2000 µl. Dabei können je nach Fluid- bzw. bevorzugt Blutmenge und - beschaffenheit bis zu 200 µl Plasma oder Serum zur Messung im Messbereich gewonnen werden. Vorzugsweise erlaubt die erfindungsgemäße Vorrichtung die Bereitstellung eines zu messenden Volumens im Messbereich zwischen ca. 15 µl und ca. 80 µl, bevorzugt zwischen ca. 20 µl und ca. 60 µl und am meisten bevorzugt von ca. 40 µl Serum oder Plasma.The filter area preferably has a capacity of between about 200 and about 2000 μl. Depending on the fluid or, preferably, the amount and texture of the blood, up to 200 μl of plasma or serum can be obtained for measurement in the measuring range. The device according to the invention preferably allows the provision of a volume to be measured in the measurement range between about 15 μl and about 80 μl, preferably between about 20 μl and about 60 μl and most preferably about 40 μl serum or plasma.
Im Rahmen der vorliegenden Erfindung erfolgt vorzugsweise die Bestimmung von Bestandteilen in Serum oder Plasma bzw. Blutserum oder Blutplasma.In the context of the present invention, it is preferable to determine constituents in serum or plasma or blood serum or blood plasma.
Unter "Plasma" versteht man vorzugsweise insbesondere die von festen Bestandteilen wie Zellen (Erythrozyten, weiße Blutzellen etc.) getrennte flüssige Phase des Blutes, die noch gerinnen kann."Plasma" is preferably understood to mean, in particular, the liquid phase of the blood which is separate from solid constituents such as cells (erythrocytes, white blood cells, etc.) and which can still coagulate.
Unter "Serum" versteht man vorzugsweise insbesondere den flüssigen Anteil des Blutes, der nach Gerinnung des Blutes durch Abtrennung der mit Thrombozyten und Gerinnungsfaktoren zum Blutkuchen vermischten zellulären Bestandteile erhalten wird."Serum" is preferably understood to mean, in particular, the liquid fraction of the blood which is obtained after coagulation of the blood by separation of the cellular constituents mixed with platelets and coagulation factors to form the blood cake.
Grundsätzlich kann im Rahmen der vorliegenden Erfindung jede Substanz mit geeigneten Nachweisreagenzien bestimmt werden. Vorzugsweise ist der nachzuweisende oder zu bestimmende Bestandteil eine in Organismen vorkommende Substanz. In Organismen vorkommende Substanzen können organischer oder anorganischer Natur sein. Anorganisch sind zum Beispiel Mineralien oder Mineralsalze, Spurenelemente, anorganische lonen, Metalle und Schwermetalle, etc.In principle, within the scope of the present invention, each substance can be determined using suitable detection reagents. Preferably, the ingredient to be detected or determined is a substance found in organisms. Organisms occurring substances may be organic or inorganic nature. Inorganic are, for example, minerals or mineral salts, trace elements, inorganic ions, metals and heavy metals, etc.
Organische Substanzen können unterschiedlichen Substanzklassen angehören. Eine Gruppe von Substanzen bilden Proteine, zu denen auch Enzyme gehören. Enzyme wandeln ihr Substrat in ein Endprodukt um. Im Rahmen der vorliegenden Erfindung können vorzugsweise sowohl das Enzym als auch das Substrat und/oder das Endprodukt bestimmt werden. Auch Nicht-Enzymproteine können vorzugsweise mit der Vorrichtung der vorliegenden Erfindung nachgewiesen oder bestimmt werden. Weitere Gruppen von organischen Substanzen umfassen Vitamine und Coenzyme, Nukleinsäuren, Cytokine, Hormone, Histone, Peptide, Zucker, etc.Organic substances can belong to different substance classes. A group of substances form proteins, including enzymes. Enzymes convert their substrate into an end product. In the context of the present invention, preferably both the enzyme and the substrate and / or the end product can be determined. Also, non-enzyme proteins may preferably be detected or determined by the apparatus of the present invention. Other groups of organic substances include vitamins and coenzymes, nucleic acids, cytokines, hormones, histones, peptides, sugars, etc.
Eine weitere Gruppe von Substanzen bilden Nukleinsäuren, die DNA und RNA in ihren einzel- und/oder doppelsträngigen Formen umfassen.Another group of substances are nucleic acids comprising DNA and RNA in their single and / or double-stranded forms.
Vorzugsweise ist der nachzuweisende oder zu bestimmende Bestandteil ein biologisches Molekül, ausgewählt aus der Gruppe umfassend DNA, RNA, Proteine, Hormone, Cytokine. Die letztgenannten Stoffe können frei oder vergesellschaftet sein mit anderen Proteinen. Beispielsweise kann DNA in Plasma oder Serum auch als Komplex mit Histonen und/oder Elastase sowie Mikrosatelliten auftreten. Weiterhin bevorzugt ist der nachzuweisende oder zu bestimmende Bestandteil die DNA/RNA von intakten oder nicht intakten Bakterien, Viren und/oder Parasiten aus mit sonstigen Partikeln verschmutzten Wasserproben. Hierbei werden Partikel durch die Filtrierung zurück gehalten, während die in Mikroorganismen enthaltene Nukleinsäure durch geeignete Fluoreszenzfarbstoffe einer Messung zugänglich gemacht werden kann.Preferably, the component to be detected or determined is a biological molecule selected from the group comprising DNA, RNA, proteins, hormones, cytokines. The latter substances may be free or associated be with other proteins. For example, DNA in plasma or serum may also occur as a complex with histones and / or elastase as well as microsatellites. Furthermore, the component to be detected or to be determined is preferably the DNA / RNA of intact or intact bacteria, viruses and / or parasites from water samples contaminated with other particles. In this case, particles are retained by the filtration, while the nucleic acid contained in microorganisms can be made accessible to a measurement by suitable fluorescent dyes.
Vorzugsweise ist der nachzuweisende oder zu bestimmende Bestandteil ein Arzneistoff. Arzneistoffe sind einem Individuum verabreichbare Stoffe zur Bekämpfung eines krankhaften Zustands oder einer Krankheit. Arzneistoffe können auch die oben genannten biologischen Moleküle sein.Preferably, the ingredient to be detected or determined is a drug. Drugs are substances which can be administered to an individual for controlling a pathological condition or disease. Drugs may also be the abovementioned biological molecules.
Am meisten bevorzugt wird DNA bestimmt bzw. gemessen. Das im Rahmen der vorliegenden Erfindung verwendete Filter bindet bevorzugt nur wenig oder keine DNA. Der gebundene Anteil beträgt vorzugsweise weniger als 30%, bevorzugt weniger als 20%, am meisten bevorzugt weniger als 10% der im Fluid bzw. Blut enthaltenen DNA.Most preferably, DNA is determined or measured. The filter used in the present invention preferably binds little or no DNA. The bound fraction is preferably less than 30%, preferably less than 20%, most preferably less than 10% of the DNA contained in the fluid or blood.
Qualitativ wie quantitativ lässt sich DNA auf vielerlei Art und Weise nachweisen. Dazu gehören PCR Verfahren ebenso wie der Nachweis durch spezifisch mit DNA interagierenden detektierbaren Agenzien. Die vorliegende Erfindung erlaubt bevorzugt die Bestimmung nicht zellgebundener DNA. Nicht zellgebundene DNA lässt sich mittels unterschiedlicher Verfahren bestimmen. Neben der Messung der Fluoreszenz nach Zugabe eines interkalierenden Farbstoffes wird auch die Messung der UV-Absorption von DNA zur Konzentrationsbestimmung herangezogen. Die hierfür notwendigen Probenvolumina sind inzwischen im niedrigen µl-Bereich angelangt (z. B. Messung mittels NanoDrop im Bereich ab 2 µl). Die untere Messgrenze für DNA liegt z. Zt. etwa bei 10 ng/ml für das Fluoreszenzverfahren.Qualitatively and quantitatively, DNA can be detected in many ways. These include PCR as well as detection by detectable agents interacting specifically with DNA. The present invention preferably permits the determination of non-cell-bound DNA. Non-cell-bound DNA can be determined by different methods. In addition to the measurement of the fluorescence after addition of an intercalating dye, the measurement of the UV absorption of DNA is also used to determine the concentration. The sample volumes required for this have now reached the low μl range (eg measurement by NanoDrop in the range from 2 μl). The lower measurement limit for DNA is z. At about 10 ng / ml for the fluorescence method.
Nach größeren Operationen, insbesondere auch mit Herz-Lungen-Maschine, aber auch nach Unfällen mit Polytraumen, Sepsis, Verbrennungen sowie nach Ischämie/Reperfusionskrankheit (nach arteriellem Verschluss) kommt es zu starken, mitunter überschießenden Aktivierungen des Immunsystems. Exemplarische, jedoch nicht abschließend, Krankheitszustände sind Operation, Polytrauma, Weichteiltrauma, Ischämie/Reperfusionskrankheit, Infarkt, Ischämie, Embolie, Infektion, Sepsis, Transplantation, Vergiftung, Eklampsie, Nebenwirkungen von Medikamenten oder von Transfusionen. Diese können vorübergehende oder bleibende Schäden in Organen verursachen, aber auch zum Tode führen. Die zelluläre Komponente dieser Immunantwort wird durch neutrophile Granulozyten vermittelt. Zur Abschätzung der Folgen der Aktivierung ist es wichtig, über das Ausmaß des Geschehens zeitnah im Bilde zu sein.After major operations, especially with heart-lung machine, but also after accidents with polytrauma, sepsis, burns and after ischemia / reperfusion disease (after arterial occlusion) there are strong, sometimes over-activations of the immune system. Exemplary, but not exclusive, disease states are surgery, polytrauma, soft tissue trauma, ischemia / reperfusion disease, infarct, ischemia, embolism, infection, sepsis, transplantation, intoxication, eclampsia, drug side effects or transfusions. These can cause temporary or permanent damage in organs, but can also lead to death. The cellular component of this immune response is mediated by neutrophil granulocytes. To assess the consequences of activation, it is important to be up-to-date about the extent of the event.
Wie in
Die vorliegende Erfindung stellt eine Vorrichtung und ein Verfahren bereit, die NETs nachzuweisen, die bereits innerhalb von Minuten nach Aktivierung der sie produzierenden Granulozyten freigesetzt werden. Der Nachweis in Proben von Patienten kann zu rechtzeitigen Reaktionen von Seiten der behandelnden Ärzte führen, die Leben retten können.The present invention provides an apparatus and method for detecting the NETs that are already released within minutes of activation of the granulocytes producing them. Proofing in patient samples can lead to timely responses from the attending physicians who can save lives.
Weitere im Blut befindliche freie DNA wird aus abgestorbenen Zellen freigesetzt. Diese Zellen können durch apoptotische oder nekrotische Ereignisse abgestorben sein. Im Zuge mancher Therapien, zum Beispiel von Krebs mit Chemo- oder Strahlentherapie wird die Apoptose von Zellen, unter anderem von Blutzellen induziert. Der Therapieerfolg lässt sich somit direkt und fein abgestuft mit der vorliegenden Erfindung nachweisen.More free DNA in the blood is released from dead cells. These cells may be dead by apoptotic or necrotic events. In the course of some therapies, for example of cancer with chemo- or Radiotherapy induces apoptosis of cells, including blood cells. The therapeutic success can thus be detected directly and finely graded with the present invention.
Vorzugsweise ist das Vorhandensein und/oder die Konzentration des Bestandteils im Messbereich, vorzugsweise in Abhängigkeit des verwendeten Detektionsreagenz, mittels Lumineszenz, Fluoreszenz, Chemilumineszenz, Elektrochemilumineszenz, spektrale Absorptionsphotometrie, Autofluoreszenz und/oder Biolumineszenz bestimmbar.Preferably, the presence and / or concentration of the component in the measuring range, preferably depending on the detection reagent used, by means of luminescence, fluorescence, chemiluminescence, electrochemiluminescence, spectral absorption photometry, autofluorescence and / or bioluminescence determinable.
Vorzugsweise ist das Filter ausgebildet, feste Bestandteile des das Filter durchfließenden Fluids abzutrennen, und insbesondere die feste und flüssige Phase des Fluids voneinander zu trennen. Einige Filtermaterialien können sich als sehr spröde oder brüchig erweisen, so dass eine Stabilisierung notwendig ist. Abhängig von der Beschaffenheit des Filters kann es ein Element zur Stabilisierung enthalten. Stabilisierungselemente sind vorzugsweise stabilisierende Umrandungen oder Rahmen oder aufgelagerte oder integrierte Netzwerke eines stabilen Materials, wie zum Beispiel Metall oder Kunststoff.Preferably, the filter is adapted to separate solid components of the fluid flowing through the filter, and in particular to separate the solid and liquid phases of the fluid from each other. Some filter materials can be very brittle or fragile, so stabilization is necessary. Depending on the nature of the filter, it may contain an element for stabilization. Stabilizing elements are preferably stabilizing frames or frames or superimposed or integrated networks of a stable material, such as metal or plastic.
Vorzugsweise ist der Fluideingangsbereich, der vorzugsweise vom Filterbereich umfasst ist, der Vorrichtung derart ausgebildet, dass ein über Umgebungsdruck liegender Druck auf das Fluid ausgeübt wird. Die Vorrichtung ist vorzugsweise derart ausgebildet, dass ein solcher Druck beim Einbringen des Fluides, vorzugsweise durch eine Spritze oder dgl, aufgebaut wird.Preferably, the fluid input region, which is preferably encompassed by the filter region, of the device is designed such that an above ambient pressure is exerted on the fluid. The device is preferably designed such that such a pressure during the introduction of the fluid, preferably by a syringe or the like, is constructed.
Bevorzugt ist die Vorrichtung derart ausgebildet, dass das Fluid unter Druck durch das Filter in den Messbereich eingebracht wird. Dieser Druck kann vorzugsweise manuell ausgeübt werden, z. B. durch den Kolben einer Spritze, die das zu messende ungefilterte Fluid enthält.Preferably, the device is designed such that the fluid is introduced under pressure through the filter in the measuring range. This pressure can preferably be exercised manually, for. B. by the piston of a syringe containing the unfiltered fluid to be measured.
Gemäß einer bevorzugten erfindungsgemäßen Ausführungsform herrscht in der Vorrichtung ein unter dem Umgebungsdruck liegender Druck, vorzugsweise ein Vakuum. Wird die zu bestimmende Probe mit der Vorrichtung in Kontakt gebracht, bewirkt der niedrige Druck bzw. das Vakuum, dass die Probe ohne von außen ausgeübte Kraft in die Vorrichtung geleitet oder gesaugt wird und im Inneren der Vorrichtung die festen Bestandteile vom Fluid abgetrennt werden. Dabei ist der Messbereich vorzugsweise aus einem vorzugsweise elastischen Material, dass bestrebt ist, eine definierte Position oder Form einzunehmen. Vorzugsweise ist die Vorrichtung aus elastischem Material, das derart verformt ist, dass das Innenvolumen der Messkammer kleiner als das der definierten Position ist, so dass es sich z.B. beim Einleiten der Probe entfaltet bzw. die Probe beim Entfalten einsaugt. Weiterhin vorzugsweise ist der Messbereich aus einem unelastischen Material, wobei der Bereich innerhalb des Messbereichs einen niedrigeren Druck als den Umgebungsdruck aufweist, bevor die Probe in die Vorrichtung gelangt.According to a preferred embodiment of the invention prevails in the device is a pressure lying below the ambient pressure, preferably a vacuum. If the sample to be determined is brought into contact with the device, causes the low pressure or the vacuum that the sample is passed or sucked without externally applied force in the device and inside the device, the solid components are separated from the fluid. In this case, the measuring range is preferably made of a preferably elastic material, which endeavors to assume a defined position or shape. Preferably, the device is made of elastic material that is deformed such that the inner volume of the measuring chamber is smaller than that of the defined position, so that it unfolds eg when introducing the sample or the sample is sucked in during deployment. Further preferably, the measurement region is made of an inelastic material, wherein the region within the measurement region has a lower pressure than the ambient pressure before the sample enters the device.
In einer weiteren bevorzugten Ausführungsform ist das Detektionsreagenz im Messbereich oder in einem kurz vor dem Messbereich befindlichen Hohlraum/ Lumen, der sich vorzugsweise zwischen Filter und Messbereich erstreckt, vorgesehen.In a further preferred embodiment, the detection reagent is provided in the measuring area or in a cavity / lumen located just before the measuring area, which preferably extends between the filter and the measuring area.
In einer weiteren bevorzugten Ausführungsform ist das Detektionsreagenz im Filter oder in räumlicher Nähe zum Filter vorgesehen.In a further preferred embodiment, the detection reagent is provided in the filter or in spatial proximity to the filter.
In einer weiteren bevorzugten Ausführungsform interagiert das Detektionsreagenz direkt oder indirekt mit dem zu bestimmenden Bestandteil. Direkte Interaktion erfolgt vorzugsweise im Fall der Bestimmung von DNA mit Reagenzien, die sich an die DNA anlagern. Dabei kann die Anlagerung kovalent oder nichtkovalent erfolgen.
Bestimmte Substanzen lagern sich in doppelsträngige und auch einzelsträngiger DNA ein, ohne eine kovalente Bindung mit der DNA einzugehen (Interkalatoren). Zum Teil gewinnen die Substanzen erst dadurch die Eigenschaft der Fluoreszenz. Durch die Akkumulation in der DNA und Bestrahlung mit Licht bestimmter Wellenlängen emittieren diese Substanzen Licht unterschiedlicher Wellenlänge, welches quantitativ messbar ist und mit der DNA-Menge korreliert. Fluoreszenzfarbstoffe können auch andere als Interkalatoren sein und durch chemische Modifikation mit der zu messenden DNA in Kontakt gebracht werden. In einer weiteren bevorzugten Ausführungsform ist das Detektionsreagenz ausgewählt aus der Gruppe umfassend Pico-Green™, Alexa- oder Sytox®-Farbstoffen, Ethidiumbromid und SYBR®-Farbstoffe.In a further preferred embodiment, the detection reagent interacts directly or indirectly with the constituent to be determined. Direct interaction is preferably in the case of the determination of DNA with reagents that attach to the DNA. In this case, the attachment can be covalent or noncovalent.
Certain substances integrate into double-stranded and single-stranded DNA without covalent binding with the DNA (intercalators). In part, the substances only gain the property of fluorescence. By accumulation in the DNA and irradiation with light of certain wavelengths, these substances emit light of different wavelengths, which is quantitatively measurable and correlated with the amount of DNA. Fluorescent dyes may also be other than intercalators and be contacted by chemical modification with the DNA to be measured. In a further preferred embodiment, the detection reagent is selected from the group comprising Pico-Green ™, Alexa or Sytox® dyes, ethidium bromide and SYBR® dyes.
Im Rahmen der vorliegenden Erfindung erfolgt bevorzugt eine quantitative Bestimmung einer Substanz im Messbereich. Dazu ist es bei Vorhandensein nur eines Detektionsreagenzes vorteilhaft, dass das Detektionsreagenz bei Interaktion mit dem Zielmolekül seine Eigenschaften dahingehend ändert, dass es detektierbar wird. Wie weiter oben beschrieben, werden Interkalatoren erst bei Einlagerung in Nukleinsäuren detektierbar, wohingegen sie im ungebundenen Zustand diese Eigenschaft nicht aufweisen. Das im Rahmen der vorliegenden Erfindung verwendete Detektionsreagenz kann bereits vor Interaktion mit dem Zielmolekül detektierbar sein, ändert jedoch vorzugsweise seine dahingehenden Eigenschaften bei Interaktion mit dem Zielmolekül. Dies erfolgt vorzugsweise durch Verschiebung des Absorptionsmaximums oder der Emissionswellenlänge eines Detektionsreagenzes.In the context of the present invention, preferably a quantitative determination of a substance in the measuring range is carried out. For this purpose, if only one detection reagent is present, it is advantageous for the detection reagent, when interacting with the target molecule, to change its properties such that it becomes detectable. As described above, intercalators become detectable only upon incorporation into nucleic acids, whereas in the unbound state they do not exhibit this property. The detection reagent used in the present invention may already be detectable prior to interaction with the target molecule, but preferably alters its pertinent properties upon interaction with the target molecule. This is preferably done by shifting the absorption maximum or the emission wavelength of a detection reagent.
Vorzugsweise umfasst die Messung der nicht zellgebundenen DNA die Bestimmung der Fluoreszenzemission nach Zugabe eines Fluoreszenzfarbstoffes zum Plasma oder Serum.The measurement of the non-cell-bound DNA preferably comprises the determination of the fluorescence emission after addition of a fluorescent dye to the plasma or serum.
Grundsätzlich können alle Fluorophore im Rahmen der Erfindung verwendet werden. Die folgende nicht vollständige Liste gibt Beispiele für geeignete Fluorophore wieder: 1,5 IAEDANS, 1,8-ANS, 4-Methylumbelliferon, 4',6-Diamidino-2-phenylindol, 5-(and-6)-Carboxy-2', 7'-Dichlorofluorescein pH 9.0, 5-Carboxy-2,7-dichlorofluorescein, 5 Carboxyfluorescein (5-FAM), 5-Carboxynapthofluorescein (pH 10), 5-Carboxytetramethylrhodamin (5-TAMRA), 5-FAM (5-Carboxyfluorescein), 5-FAM pH 9.0, 5-HAT (Hydroxy Tryptamin), 5-Hydroxy Tryptamin (HAT), 5-ROX (5-Carboxy-X-rhodamin, triethylammonium salz), 5-ROX (Carboxy-X-rhodamin), 5-ROX pH 7.0, 5-TAMRA (5-Carboxytetramethylrhodamin), 6 JOE, 6-Carboxyrhodamin 6G, 6-Carboxyrhodamin 6G pH 7.0, 6-Carboxyrhodamin 6G hydrochlorid, 6-CR 6G, 6-HEX, SE pH 9.0, 6-JOE, 6-TET, SE pH 9.0, 7-AAD (7-Amino-actinomycin D), 7-Amino-4-methylcoumarin, 7-Aminoactinomycin D (7-AAD), 7-Hydroxy-4-methylcoumarin, 9-Amino-6-chloro-2-methoxyacridin, ABQ, Acid Fuchsin, ACMA, ACMA (9-Amino-6-chloro-2-methoxyacridin), Acridin Homodimer, Acridinorange, Acridinorange + DNA, Acridinorange, DNA & RNA, Acridinrot, Acridingelb, Acriflavin, Acriflavin Feulgen SITSA, Aequorin, AFPs, Alexa 405, Alexa 430, Alexa 488, Alexa 546, Alexa 568, Alexa 594, Alexa Fluor 350™, Alexa Fluor 430 Antikörperkonjugat pH 7.2, Alexa Fluor 430™, Alexa Fluor 488 Antikörperkonjugat pH 8.0, Alexa Fluor 488 Hydrazidwasser, Alexa Fluor 488™, Alexa Fluor 532™, Alexa Fluor 546™, Alexa Fluor 568 Antikörperkonjugat pH 7.2, Alexa Fluor 568™, Alexa Fluor 594™, Alexa Fluor 610 R-phycoerythrin-Streptavidin pH 7.2, Alexa Fluor 647 R-phycoerythrin-Streptavidin pH 7.2, Alexa Fluor 633™, Alexa Fluor 647™, Alexa Fluor 660™, Alexa Fluor 680™, Alexa Fluor 700, Alexa Fluor 750, Alizarin Complexon, Alizarin Rot, Allophycocyanin (APC), AMC, AMCA-S, AMCA (Aminomethylcoumarin), AMCA-X, Aminoactinomycin D, Aminocoumarin, Aminomethylcoumarin (AMCA), Anilinblau, Anthrocylstearat, APC (Allophycocyanin), APC-Cy7, APTRA-BTC, APTS, Astrazon Brilliant Red 4G, Astrazon Orange R, Astrazon Red 6B, Astrazon, Yellow 7 GLL, Atabrin, ATTO-TAG™ CBQCA, ATTO-TAG™ FQ, Auramin, Aurophosphin, Aurophosphin G, BAO 9(Bisaminophenyloxadiazol), BCECF (high pH), BCECF (low pH), BCECF pH 5.5, BCECF pH 9.0, Berberinsulfat, Beta Lactamase, BFP, BFP/GFP FRET, Bimane, bis-Acridinorange, Bisbenzamid, Bisbenzimid (Hoechst), bis-BTC, Blancophor FFG, Blancophor SV, BOBO-3-DNA, BOBO™ -1, BOBO™ -3, Bodipy 492/515, Bodipy 493/503, Bodipy 500/510, Bodipy 505/515, Bodipy 530/550, Bodipy 542/563, Bodipy 558/568, Bodipy 564/570, Bodipy 576/589, Bodipy 581/591, Bodipy 630/650-X, Bodipy 650/665-X, Bodipy 665/676, Bodipy FI, Bodipy FL ATP, BODIPY FL conjugate, BODIPY FL, MeOH, Bodipy FI-Ceramid, Bodipy R6G SE, Bodipy TMR, Bodipy TMR-X Konjugat, Bodipy TMR-X, SE, Bodipy TR, Bodipy TR ATP, BODIPY TR-X Phallacidin pH 7.0, Bodipy TR-X SE, BODIPY TR-X, MeOH, BODIPY TR-X, SE, BOPRO-3, BO-PRO-3-DNA, BO-PRO™ -1, BO-PRO™ -3, Brilliant Sulphoflavin FF, BTC, BTC-5N, Calcein, Calceinblau, Calcein pH 9.0, Calcein/Ethidium Homodimer, Calcium Crimson, Calcium Crimson Ca2+, Calcium Crimson™, Calcium Green, Calcium Green-1, Calcium Green-1 Ca2+, Calcium Green-2, Calcium Green-5N, Calcium Green-C18, Calcium Orange, Calcofluor White, Carboxy-X-rhodamine (5-ROX), Cascade Blue, Cascade Blue BSA pH 7.0, Cascade Blue™, Cascade Yellow, Cascade Yellow antibody conjugate pH 8.0, Catecholamine, CCF2 (GeneBlazer), CFDA, CFP, CFP (Cyan Fluorescent Protein), CFP/YFP FRET, Chlorophyll, Chromomycin A, Chromomycin A, CI-NERF pH 2.5, CI-NERF pH 2.5, CI-NERF pH 6.0, CI-NERF pH 6.0, CL-NERF, CMFDA, Coelenterazin, Coelenterazin cp, Coelenterazin f, Coelenterazin fcp, Coelenterazin h, Coelenterazin hcp, Coelenterazin ip, Coelenterazin n, Coelenterazin O, Coumarin Phalloidin, C-phycocyanine, CPM, CTC, CTC Formazan, Cy2™, Cy3.1 8, Cy3.5™, Cy3™, Cy5.1 8, Cy5.5™, Cy5™, Cy7™, Cyan 3, Cyan 6" Cyan GFP, cyclic AMP Fluorosensor (FiCRhR), CyQuant, CyQUANT GR-DNA, Dabcyl, Dansyl, Dansylamin, Dansylcadaverine, Dansylchlorid, Dansyl DHPE, Dansylfluorid, DAPI, Dapoxyl, Dapoxyl 2, Dapoxyl 3, DCFDA, DCFH (Dichlorodihydrofluoresceindiacetat), DDAO, DHR (Dihydorhodamin 123), Di-4-ANEPPS, Di-8 ANEPPS, Di-8-ANEPPS (non-ratio), Di-8-ANEPPS-lipid, DiA (4-Di-16-ASP), Dichlorodihydrofluoresceindiacetat (DCFH), DiD, DIDS, Dihydorhodamin 123 (DHR), Dihydroethidium, DiI (DiIC18(3)), DiIC18 ("DiD") Dinitrophenol, DiO (DiOC18(3)), DiR, DiR (DiIC18(7)), DM-NERF (high pH), DM-NERF pH 4.0, DM-NERF pH 7.0, DNP, Dopamin, DsRed, Draq5, DTAF, DY-630-NHS, DY-635-NHS, EBFP, ECFP, eCFP (Enhanced Cyan Fluorescent Protein), EGFP, eGFP (Enhanced Green Fluorescent Protein), ELF 97, Eosin, Eosin Antikörperkonjugat pH 8.0, Erythrosin, Erythrosin ITC, Ethidiumbromid, Ethidiummonoazid, Ethidium Homodimer, Ethidium Homodimer -1 (EthD-1), Ethidium Homodimer-1-DNA, Ethidium Homodimer-2, Euchrysin, EukoLight, Europium-(III)-chlorid, EYFP, eYFP (Enhanced Yellow Fluorescent Protein), Fast Blue, FDA, Feulgen (Pararosanilin), FIF (Formaldehyd Induced Fluorescence), FITC, FITC Antikörper, FITC Antikörperkonjugat pH 8.0, Flazo Orange, Fluo-3, Fluo-3 Ca2+, Fluo-4, Fluorescein, Fluorescein (FITC), Fluorescein 0.1 M NaOH, Fluorescein Antikörperkonjugat pH 8.0, Fluoresceindextran pH 8.0, Fluoresceindiacetat, Fluorescein pH 9.0, Fluoro-Emerald, Fluoro-Gold (Hydroxystilbamidin), Fluor-Ruby, FluorX, FM 1-43, FM 1-43 lipid, FM 1-43™, FM 4-64, Fura Red Ca2+, Fura Red, high Ca, Fura Red, low Ca, Fura Red™ (high pH), Fura Red™/Fluo-3, Fura-2, high calcium, Fura-2, low calcium, Fura-2/BCECF, Genacryl Brilliant Red B, Genacryl Brilliant Yellow 10GF, Genacryl Pink 3G, Genacryl Yellow 5GF, GeneBlazer (CCF2), GFP (S65T), GFP red shifted (rsGFP), GFP wild type, non-UV excitation (wtGFP), GFP wild type, UV excitation (wtGFP), GFPuv, Gloxalic Acid, Granular Blue, Haematoporphyrin, HcRed, Hexidium iodide, Hoechst 33258 (bis-benzimid), Hoechst 33258, Hoechst 33342, Hoechst 34580, HPTS, Hydroxycoumarin, Hydroxystilbamidin, Hydroxystilbamidin (FluoroGold), Hydroxytryptamin, Indo-1, high calcium, Indo-1, low calcium, Indodicarbocyanin (DiD), Indotricarbocyanin (DiR), Intrawhite, Cf, JC-1, JO-JO-1, JO-PRO-1, LaserPro, Laurodan, LDS 751, LDS 751 (DNA), LDS 751 (RNA), Leucophor PAF, Leucophor SF, Leucophor WS, Lissamine Rhodamine, Lissamine Rhodamine B, LIVE/DEAD Kit Animal Cells, , LOLO-1, LO-PRO-1, Lucifer Yellow, Lucifer Yellow, CH, Lyso Tracker Blue, Lyso Tracker Blue-White, Lyso Tracker Green, Lyso Tracker Red, Lyso Tracker Yellow, LysoSensor Blue, LysoSensor Green, LysoSensor Green pH 5.0, LysoSensor Yellow pH 3.0, LysoSensor Yellow/Blue, Mag Green, Magdala Red (Phloxin B), Mag-Fura Red, Mag-Fura-2, Mag-Fura-5, Mag-Indo-1, Magnesium Green, Magnesium Green Mg2+, Magnesiumorange, Malachitgrün, Marina Blue, Maxilon Brilliant Flavin 0 GFF, Maxilon Brilliant Flavin 8 GFF, Merocyanin, Methoxycoumarin, MitoTracker Green, Mitotracker Green FM, MitoTracker Green FM, MeOH, Mitotracker Orange, MitoTracker Red, MitoTracker Red, MeOH, Mitramycin, Monobromobiman, Monobromobiman (mBBr-GSH), Monochlorobiman, MPS (Methyl Green Pyronine Stilbene), MRFP, NBD, NBD Amin, NBD-X, NBD-X, MeOH, NeuroTrace 500/525, green fluorescent Nissl stain-RNA, Nile Blue, EtOH, Nilrot, Nilrot-lipid, Nissl, Nitrobenzoxadidol, Noradrenalin, Nuclear Fast Red, Nuclear Yellow, Nylosan Brilliant lavin E8G, OliGreen®, Oregon Green, Oregon Green 488, Oregon Green 488 antibody conjugate pH 8.0, Oregon Green 488-X, Oregon Green 514, Oregon Green 514 antibody conjugate pH 8.0, Oregon Green™, Oregon Green™ 488, Oregon Green™ 500, Oregon Green™ 514, Pacific Blue, Pacific Blue Antikörperkonjugat pH 8.0, Pararosanilin (Feulgen), PBFI, PE-Cy5, PE-Cy7, PerCP, PerCP-Cy5.5, PE-TexasRed [Red 613], Phloxin B (Magdala Red), Phorwite AR, Phorwite BKL, Phorwite Rev, Phorwite RPA, Phosphin 3R, PhotoResist, Phycoerythrin B [PE], Phycoerythrin R [PE], PicoGreen dsDNA quantitation reagent, PKH26 (Sigma), PKH67, PMIA, Pontochrome Blue Black, POPO-1, POPO-1-DNA, POPO-3, POPO™-3 iodide, PO-PRO-1, PO-PRO-1-DNA, PO-PRO-3, Primulin, Procion Yellow, Propidiumiodid (PI), Propidiumiodid-DNA, PyMPO, Pyren, Pyronin, Pyronin B, Pyrozal Brilliant Flavin 7GF, QSY 7, Quinacrin Mustard, Red 613 [PE-TexasRed], Resorufin, RH 414, Rhod-2, Rhodamin, Rhodamin 110, Rhodamin 110 pH 7.0, Rhodamin 123, Rhodamin 123, MeOH, Rhodamin 5 GLD, Rhodamin 6G, Rhodamin B, Rhodamin B 200, Rhodamin B extra, Rhodamin BB, Rhodamin BG, Rhodamin Green, Rhodamin Phallicidin, Rhodamin Phalloidin, Rhodaminrot, Rhodamin WT, Rhodamingrün pH 7.0, Rhodol Green POPO-1-DNA pH 8.0, Ribogreen, Rose Bengal, R-phycocyanin, R-phycoerythrin (PE), R-Phycoerythrin pH 7.5, RsGFP, S65A, S65C, S65L, S65T, Sapphire GFP, SBFI, Serotonin, Sevron Brilliant Red 2B, Sevron Brilliant Red 4G, Sevron Brilliant Red B, Sevron Orange, Sevron Yellow L, sgBFP™, sgBFP™ (super glow BFP), sgGFP™ (super glow GFP), SITS, SITS (Primuline), SITS (Stilbene Isothiosulphonic Acid), SNAFL calcein, SNAFL-1, SNAFL-2, SNARF calcein, SNARF1, Sodium Green, Sodium Green Na+, Spectrum Red, SpectrumAqua, SpectrumGreen, SpectrumOrange, SPQ (6-methoxy-N-(3-sulfopropyl)quinolinium), Stilbene, Sulphorhodamine B can C, Sulphorhodamine G Extra, SYBR® Green, SYBR® Green I, SYBR® Green II, SYBR® Gold, SYBR® Safe DNA, SYPRO Ruby, SYTO 11, SYTO 12, SYTO 13, SYTO 13-DNA, SYTO 14, SYTO 15, SYTO 16, SYTO 17, SYTO 18, SYTO 20, SYTO 21, SYTO 22, SYTO 23, SYTO 24, SYTO 25, SYTO 40, SYTO 41, SYTO 42, SYTO 43, SYTO 44, SYTO 45, SYTO 45-DNA, SYTO 59, SYTO 60, SYTO 61, SYTO 62, SYTO 63, SYTO 64, SYTO 80, SYTO 81, SYTO 82, SYTO 83, SYTO 84, SYTO 85, SYTOX Blue, SYTOX Blue-DNA, SYTOX Green, SYTOX Orange, Tetracyclin, Tetramethylrhodamin (TRITC), Texas Red™, Texas Red-X POPO-1-DNA pH 7.2, Texas Red-X™ conjugate, Thiadicarbocyanin (DiSC3), Thiazinrot R, Thiazolorange, Thioflavin 5, Thioflavin S, Thioflavin TCN, Thiolyte, Tinopol CBS (Calcofluor White), TMR, TO-PRO®-1 iodide, TO-PRO®-3 iodide, TO-PRO-1, TO-PRO-1-DNA, TO-PRO-3, TO-PRO-5, TOTO-1, TOTO-1-DNA, TOTO-3, TriColor (PE-Cy5), TRITC TetramethylRodaminelsoThioCyanat, True Blue, TruRed, Ultralite, Uranin B, Uvitex SFC, wt GFP, WW 781, X-Rhod-1 Ca2+, X-Rhodamin, XRITC, Xylenorange, Y66F, Y66H, Y66W, Yellow GFP, YFP, YO-PRO®-1 iodide, YO-PRO-1, YO-PRO-1-DNA, YO-PRO-3, YOYO-1, YOYO-1-DNA, YOYO-3In principle, all fluorophores can be used within the scope of the invention. The following non-exhaustive list gives examples of suitable fluorophores: 1.5 IAEDANS, 1,8-ANS, 4-methylumbelliferone, 4 ', 6-diamidino-2-phenylindole, 5- (and-6) -carboxy-2' , 7'-dichlorofluorescein pH 9.0, 5-carboxy-2,7-dichlorofluorescein, 5 carboxyfluorescein (5-FAM), 5-carboxynapthofluorescein (pH 10), 5-carboxytetramethylrhodamine (5-TAMRA), 5-FAM (5-carboxyfluorescein ), 5-FAM pH 9.0, 5-HAT (hydroxy tryptamine), 5-hydroxy tryptamine (HAT), 5-ROX (5-carboxy-X-rhodamine, triethylammonium salt), 5-ROX (carboxy-X-rhodamine) , 5-ROX pH 7.0, 5-TAMRA (5-carboxytetramethylrhodamine), 6 JOE, 6-carboxyrhodamine 6G, 6-carboxyrhodamine 6G pH 7.0, 6-carboxyrhodamine 6G hydrochloride, 6-CR 6G, 6-HEX, SE pH 9.0, 6-JOE, 6-TET, SE pH 9.0, 7-AAD (7-amino-actinomycin D), 7-amino-4-methylcoumarin, 7-aminoactinomycin D (7-AAD), 7-hydroxy-4-methylcoumarin, 9-Amino-6-chloro-2-methoxyacridine, ABQ, Acid Fuchsin, ACMA, ACMA (9-amino-6-chloro-2-methoxyacridine), acridine homodimer, acridine orange, acridine orange + DNA, acridine orange, DNA & RNA, acridine red, acridine yellow, acriflavine, acriflavine Feulgen SITSA, aequorin, AFPs, Alexa 405 , Alexa 430, Alexa 488, Alexa 546, Alexa 568, Alexa 594, Alexa Fluor 350 ™, Alexa Fluor 430 Antibody Conjugate pH 7.2, Alexa Fluor 430 ™, Alexa Fluor 488 Antibody Conjugate pH 8.0, Alexa Fluor 488 Hydrazide Water, Alexa Fluor 488 ™, Alexa Fluor 532 ™, Alexa Fluor 546 ™, Alexa Fluor 568 Antibody Conjugate pH 7.2, Alexa Fluor 568 ™, Alexa Fluor 594 ™, Alexa Fluor 610 R-phycoerythrin streptavidin pH 7.2, Alexa Fluor 647 R-phycoerythrin streptavidin pH 7.2, Alexa Fluor 633 ™, Alexa Fluor 647 ™, Alexa Fluor 660 ™, Alexa Fluor 680 ™, Alexa Fluor 700, Alexa Fluor 750, Alizarin Complexone, Alizarin Red, Allophycocyanin (APC), AMC, AMCA-S, AMCA (Aminomethyl Coumarin), AMCA -X, amino actinomycin D, aminocoumarin, aminomethyl coumarin (AMCA), aniline blue, anthrocyl esters arat, APC (allophycocyanin), APC-Cy7, APTRA-BTC, APTS, Astrazon Brilliant Red 4G, Astrazon Orange R, Astrazon Red 6B, Astrazon, Yellow 7 GLL, Atabrin, ATTO-TAG ™ CBQCA, ATTO-TAG ™ FQ, Auramine, aurophosphine, aurophosphin G, BAO 9 (bisaminophenyloxadiazole), BCECF (high pH), BCECF (low pH), BCECF pH 5.5, BCECF pH 9.0, berberine sulfate, beta lactamase, BFP, BFP / GFP FRET, bimane, bis-acridine orange , Bisbenzamide, bisbenzimide (Hoechst), bis-BTC, Blancophor FFG, Blancophor SV, BOBO-3 DNA, BOBO ™ -1, BOBO ™ -3, Bodipy 492/515, Bodipy 493/503, Bodipy 500/510, Bodipy 505/515, Bodipy 530/550, Bodipy 542/563, Bodipy 558/568, Bodipy 564/570, Bodipy 576/589, Bodipy 581/591, Bodipy 630/650-X, Bodipy 650/665-X, Bodipy 665 / 676, Bodipy FI, Bodipy FL ATP, BODIPY FL conjugate, BODIPY FL, MeOH, Bodipy FI-Ceramide, Bodipy R6G SE, Bodipy TMR, Bodipy TMR-X Conjugate, Bodipy TMR-X, SE, Bodipy TR, Bodipy TR ATP BODIPY TR-X Phallacidin pH 7.0, Bodipy TR-X SE, BODIPY TR-X, MeOH, BODIPY TR-X, SE, BOPRO-3, BO-PRO-3 DNA, BO-PRO ™ -1, BO-PRO ™ -3, Brilliant Sulfoflavin FF, BTC, BTC-5N, Calcein, Calcein Blue, Calcein pH 9.0, Calcein / Ethidium Homodimer, Calcium Crimson, Calcium Crimson Ca2 +, Calcium Crimson ™ , Calcium Green, Calcium Green-1, Calcium Green-1 Ca2 +, Calcium Green-2, Calcium Green-5N, Calcium Green-C18, Calcium Orange, Calcofluor White, Carboxy-X-rhodamine (5-ROX), Cascade Blue, Cascade Blue BSA pH 7.0, Cascade Blue ™ , Cascade Yellow, Cascade Yellow antibody conjugate pH 8.0, Catecholamines, CCF2 (Gene Blazer), CFDA, CFP, CFP (Cyan Fluorescent Protein), CFP / YFP FRET, Chlorophyll, Chromomycin A, Chromomycin A, CI NERF pH 2.5, CI NERF pH 2.5, CI NERF pH 6.0, CI -NERF pH 6.0, CL-NERF, CMFDA, coelenterazine, coelenterazine cp, coelenterazine f, coelenterazine fcp, coelenterazine h, coelenterazine hcp, coelenterazine ip, coelenterazine n, coelenterazine O, coumarin phalloidin, C-phycocyanines, CPM, CTC, CTC formazan , Cy2 ™, Cy3.1 8, Cy3.5 ™, Cy3 ™, Cy5.1 8, Cy5.5 ™, Cy5 ™, Cy7 ™, Cyan 3, Cyan 6 "cyan GFP, cyclic AMP fluorosensor (FiCRhR), CyQuant , CyQUANT GR-DNA, Dabcyl, Dansyl, Dansylamine, Dansylcadaverine, Dansylchloride, Dansyl DHPE, Dansylfluoride, DAPI, Dapoxyl, Dapoxyl 2, Dapoxyl 3, DCFDA, DCFH (Dichlorodihydrofluorescein diacetate), DDAO, DHR (Dihydorhodamine 123), Di-4- ANEPPS, Di-8 ANEPPS, Di-8-ANEPPS (non-ratio), Di-8-ANEPPS-lipid, DiA (4-Di-16-ASP), Dichlorodihydrofluorescein diacetate (DCFH), DiD, DIDS, Dihydorhodamine 123 (DHR ), Dihydroethidium, DiI (DiIC18 (3)), di IC 18 ("DiD") dinitrophenol, DiO (DiOC18 (3)), DiR, DiR (DiIC18 (7)), DM-NERF (high pH), DM-NERF pH 4.0, DM-NERF pH 7.0, DNP, dopamine , DsRed, Draq5, DTAF, DY-630-NHS, DY-635-NHS, EBFP, ECFP, eCFP (Enhanced Cyan Fluorescent Protein), EGFP, Enhanced Green Fluorescent Protein (eGFP), ELF 97, Eosin, Eosin Antibody Conjugate pH 8.0 , Erythrosine, Erythrosine ITC, Ethidium Bromide, Ethidium Monoazide, Ethidium Homodimer, Ethidium Homodimer -1 (EthD-1), Ethidium Homodimer 1 DNA, Ethidium Homodimer-2, Euchrysine, EukoLight, Europium (III) Chloride, EYFP, eYFP (Enhanced Yellow Fluorescent Protein), Fast Blue, FDA, Feulgen (Pararosaniline), FIF (Formaldehyde Induced Fluorescence), FITC, FITC Antibody, FITC Antibody Conjugate pH 8.0, Flazo Orange, Fluo-3, Fluo-3 Ca2 +, Fluo-4, Fluorescein, fluorescein (FITC), fluorescein 0.1 M NaOH, fluorescein antibody conjugate pH 8.0, fluorescein indextran pH 8.0, fluorescein diacetate, fluorescein pH 9.0, fluoro-emerald, fluoro-gold (hydroxystilbamidine), fluoro-ruby, fluorine X, FM 1-43, FM 1-43 lipid, FM 1-43 ™, FM 4-64, Fura Red Ca2 +, Fura Red, high Ca, Fura Red, low Ca, Fura Red ™ (high pH), Fura Red ™ / Fluo-3, Fura-2, high calcium, Fura-2, low calcium, Fura-2 / BCECF, Genacryl Brilliant Red B, Genacryl Brilliant Yellow 10GF, Genacryl Pink 3G, Genacryl Yellow 5GF, Gene Blazer (CCF2), GFP (S65T), GFP red shifted (rsGFP), GFP wild type, non-UV excitation (wtGFP), GFP wild type, UV excitation (wtGFP), GFPuv, Gloxalic Acid, Granular Blue, Haematoporphyrin, HcRed, Hexidium iodide, Hoechst 33258 (bisbenzimid), Hoechst 33258, Hoechst 33342, Hoechst 34580, HPTS, hydroxycoumarin, hydroxystilbamidine, hydroxystilbamidine (FluoroGold), hydroxytryptamine, indo-1, high calcium, indo-1, low calcium, indodicarbocyanine (DiD), indotricarbocyanine (DiR), Intrawhite, Cf, JC-1, JO-JO-1, JO-PRO-1, LaserPro, Laurodan, LDS 751, LDS 751 (DNA), LDS 751 (RNA), Leucophor PAF Leucophor SF, Leucophore WS, Lissamine Rhodamine, Lissamine Rhodamine B, LIVE / DEAD Kit Animal Cells, LOLO-1, LO-PRO-1, Lucifer Yellow, Lucifer Yellow, Lyso Tracker Blue, Lyso Tracker Blue-White, Lyso Tracker Green, Lyso Tracker Red, Lyso Tracker Yellow, LysoSensor Blue, LysoSensor Green, LysoSensor Green pH 5.0, LysoSensor Yellow pH 3.0, LysoSensor Yellow / Blue, Mag Green, Magdala Red (Phloxin B), Mag-Fura Red, Mag Fura-2, Mag-Fura-5, Mag-Indo-1, Magnesium Green, Magnesium Green Mg2 +, Magnesium Orange, Malachite Green, Marina Blue, Maxilon Brilliant Flavin 0 GFF, Maxilon Brilliant Flavin 8 GFF, Merocyanine, Methoxycoumarin, MitoTracker Green, Mitotracker Green FM, MitoTracker Green FM, MeOH, Mitotracker Orange, MitoTracker Red, MitoTracker Red, MeOH, Mitramycin, Monobromobimane, Monobromobimane (mBBr-GSH), Monochlorobimane, MPS (Methyl Green Pyronine Stilbene) , MRFP, NBD, NBD amine, NBD-X, NBD-X, MeOH, NeuroTrace 500/525, green fluorescent Nissl stain RNA, Nile Blue, EtOH, Nile Red, Nile Red Lipid, Nissl, Nitrobenzoxadidol, Norepinephrine, Nuclear Fast Red , Nuclear Yellow, Nylosan Brilliant Lavin E8G, OliGreen®, Oregon Green, Oregon Green 488, Oregon Green 488 antibody conjugate pH 8.0, Oregon Green 488-X, Oregon Green 514, Oregon Green 514 antibody conjugate pH 8.0, Oregon Green ™ , Oregon Green ™ 488, Oregon Green ™ 500, Oregon Green ™ 514, Pacific Blue, Pacific Blue Antibody Conjugate pH 8.0, Pararosaniline (Feulgen), PBFI, PE-Cy5, PE-Cy7, PerCP, PerCP-Cy5.5, PE-TexasRed [ Red 613], Phloxine B (Magdala Red), Phorwite AR, Phorwite BKL, Phorwite Rev, Phorwite RPA, Phosphine 3R, PhotoResist, Phycoerythrin B [PE], Phycoerythrin R [PE], PicoGreen dsDNA quantitation reagent, PKH26 (Sigma), PKH67, PMIA, Pontochrome Blue Black, POPO-1, POPO-1 DNA, POPO-3, POPO ™ 3-iodide, PO-PRO-1, PO-PRO-1 DNA, PO-PRO-3, Primulin, Procion Yellow, Propidium Iodide (PI), Propidium Iodide DNA, PyMPO, Pyrene, Pyronine, Pyronine B, Pyrozal Brilliant Flavin 7GF, QSY 7, Quinacrine Mustard, Red 613 [PE-Texas Red], Resorufin, RH 414, Rhod-2, Rhodamine, Rhodamine 110, Rhodamine 110 pH 7.0, Rhodamine 123, Rhodamine 123, MeOH, Rhodamine 5 GLD, Rhodamine 6G, Rhodamine B, Rhodamine B 200, Rhodamine B extra, Rhodamine BB, Rhodamine BG, Rhodamine Green, Rhodamine Phallicidin, Rhodamine Phalloidin, Rhodamine Red, Rhodamine WT, Rhodamine Green pH 7.0, Rhodol Green POPO-1 DNA pH 8.0, Ribogreen, Rose Bengal, R-phycocyanin, R-phycoerythrin (PE), R-Phycoerythrin pH 7.5, RsGFP, S65A, S65C, S65L, S65T, Sapphire GFP, SBFI, Serotonin, Sevron Brilliant Red 2B, Sevron Brilliant Red 4G, Sevron Brilliant Red B, Sevron Orange, Sevron Yellow L, sgBFP ™ , sgBFP ™ (super glow BFP), sgGFP ™ (super glow GFP), SITS, SITS (Primuline), SITS (Isothiosulphonic Acid Style Level), SNAFL calcein, SNAFL-1, SNAFL-2, SNARF calcein, SNARF1, Sodium Green, Sodium Green Na +, Spectrum Red, Spectrum Aqua, Spectrum Green, Spectrum Orange, SPQ (6-methoxy-N- (3- sulfopropyl) quinolinium), stilbenes, sulphorhodamine B can C, sulphorhodamine G Extra, SYBR® Green, SYBR® Green I, SYBR® Green II, SYBR® Gold, SYBR® Safe DNA, SYPR O Ruby, SYTO 11, SYTO 12, SYTO 13, SYTO 13 DNA, SYTO 14, SYTO 15, SYTO 16, SYTO 17, SYTO 18, SYTO 20, SYTO 21, SYTO 22, SYTO 23, SYTO 24, SYTO 25, SYTO 40, SYTO 41, SYTO 42, SYTO 43, SYTO 44, SYTO 45, SYTO 45-DNA, SYTO 59, SYTO 60, SYTO 61, SYTO 62, SYTO 63, SYTO 64, SYTO 80, SYTO 81, SYTO 82, SYTO 83, SYTO 84, SYTO 85, SYTOX Blue, SYTOX Blue DNA, SYTOX Green, SYTOX Orange, Tetracycline, Tetramethyl Rhodamine (TRITC), Texas Red ™ , Texas Red-X POPO-1 DNA pH 7.2, Texas Red-X ™ conjugate, thiadicarbocyanine (DiSC3), thiazine red R, thiazole orange, thioflavin 5, thioflavine S, thioflavin TCN, thiolyte, Tinopol CBS (Calcofluor White), TMR, TO-PRO®-1 iodide, TO-PRO®-3 iodide, TO -PRO-1, TO-PRO-1 DNA, TO-PRO-3, TO-PRO-5, TOTO-1, TOTO-1 DNA, TOTO-3, TriColor (PE-Cy5), TRITC TetramethylRodaminium ToothioCyanate, True Blue, TruRed, Ultralite, Uranin B, Uvitex SFC, wt GFP, WW 781, X-Rhod-1 Ca 2+, X-Rhodamine, XRITC, Xylene Orange, Y66F, Y66H, Y66W, Yellow GFP, YFP, YO-PRO®-1 iodide, YO-PRO-1, YO-PRO-1 DNA, YO-PRO-3, YOYO-1, YOYO-1 DNA, YOYO-3
Besonders bevorzugt sind hierbei 4',6-diamidino-2-Phenylindol, 7-AAD (7-aminoActinomycin D), Acridineorange, DNA & RNA, Acridinrot, Alexa Fluor 594™, Alexa Fluor 610 R-Phycoerythrin Streptavidin pH 7.2, Alexa Fluor 647 R-Phycoerythrin Streptavidin pH 7.2, Alexa Fluor 633™, Alexa Fluor 647™, Alexa Fluor 660™, Alexa Fluor 680™, Alexa Fluor 700, Alexa Fluor 750, Allophycocyanin (APC), BOBO-3-DNA, BOBO™ -3, Bodipy 650/665-X, Cy5.5™, Cy5™, DAPI, DDAO, Draq5, Ethidiumbromid, Ethidiummonoazid, Ethidium Homodimer, Ethidium Homodimer-1 (EthD-1), Ethidium Homodimer-1-DNA, Ethidium Homodimer-2, Hoechst 33258, Hoechst 33342, LDS 751, LDS 751 (DNA), LOLO-1,MitoTracker Red, Nile Blue-EtOH, OliGreen®, PicoGreen dsDNA Quantifizierungsreagenz, POPO-1-DNA, PO-PRO-1-DNA, Propidiumiodid (PI), Propidiumiodid-DNA, Ribogreen, SYBR® Green I, SYBR® Green II, SYBR® Gold, SYBR® Safe DNA, SYPRO Ruby, SYTO 60, SYTO 61, SYTO 62, SYTO 63, SYTO 64, SYTOX Orange, Texas Red™, TO-PRO-1-DNA, TO-PRO-3, TO-PRO-5, TOTO-1-DNA, TOTO-3,YO-PRO-1-DNA, YO-PRO-3, YOYO-1, YOYO-1-DNA und YOYO-3.Particularly preferred here are 4 ', 6-diamidino-2-phenylindole, 7-AAD (7-aminoActinomycin D), acridine orange, DNA & RNA, acridine red, Alexa Fluor 594 ™, Alexa Fluor 610 R-Phycoerythrin streptavidin pH 7.2, Alexa Fluor 647 R-Phycoerythrin Streptavidin pH 7.2, Alexa Fluor 633 ™, Alexa Fluor 647 ™, Alexa Fluor 660 ™, Alexa Fluor 680 ™, Alexa Fluor 700, Alexa Fluor 750, allophycocyanin (APC), BOBO-3 DNA, BOBO ™ -3, Bodipy 650/665-X, Cy5.5 ™ , Cy5 ™ , DAPI, DDAO, Draq5, ethidium bromide , Ethidium monoazide, ethidium homodimer, ethidium homodimer-1 (EthD-1), ethidium homodimer-1 DNA, ethidium homodimer-2, Hoechst 33258, Hoechst 33342, LDS 751, LDS 751 (DNA), LOLO-1, MitoTracker Red, Nile Blue-EtOH, OliGreen®, PicoGreen dsDNA quantitation reagent, POPO-1 DNA, PO-PRO-1 DNA, propidium iodide (PI), propidium iodide DNA, Ribogreen, SYBR® Green I, SYBR® Green II, SYBR® Gold , SYBR® Safe DNA, SYPRO Ruby, SYTO 60, SYTO 61, SYTO 62, SYTO 63, SYTO 64, SYTOX Orange, Texas Red ™ , TO-PRO-1 DNA, TO-PRO-3, TO-PRO-5 , TOTO-1 DNA, TOTO-3, YO-PRO-1 DNA, YO-PRO-3, YOYO-1, YOYO-1 DNA and YOYO-3.
Am meisten bevorzugt ist Pico-Green™ und/oder SYTOX Green.Most preferred is Pico-Green ™ and / or SYTOX Green.
Dabei liegt die Dosis an Pico-Green™ vorzugsweise bei etwa 0,01 bis 5 µl Reagenz, bevorzugt bei 0.05 bis 2 µl, noch weiter bevorzugt 0,1 bis 0.5 µl Reagenz, am meisten bevorzugt bei 0,15 bis 0,3 µl Reagenz pro Messung bei ca. 40 µl Probenvolumen. Die Menge an verwendetem Reagenz wird dabei dem Probenvolumen angepasst. Bei Vorhandensein des Detektionsreagenzes in fester Form entspricht die Menge an Feststoff in ihrem Gehalt an Detektionsreagenz dem Gehalt an gelöstem Feststoff in o.g. Volumina.The dose of Pico-Green ™ is preferably about 0.01 to 5 μl of reagent, preferably 0.05 to 2 μl, more preferably 0.1 to 0.5 μl of reagent, most preferably 0.15 to 0.3 μl Reagent per measurement at approx. 40 μl sample volume. The amount of reagent used is adjusted to the sample volume. In the presence of the detection reagent in solid form, the amount of solid in its content of detection reagent corresponds to the content of dissolved solid in o.g. Volumes.
Vorzugsweise weist die Öffnung der Vorrichtung ein Ein-Wege-Ventil auf.
Weiterhin vorzugsweise weist die Öffnung ein Luer-Lock auf. Ferner bevorzugt ist der Filterbereich durch eine, vorzugsweise elastische, Folie ausgebildet bzw. abgegrenzt. Die Folie ist vorzugsweise aus einem künstlichen oder natürlichen Polymer oder auch Mischpolymer.Preferably, the opening of the device has a one-way valve.
Further preferably, the opening has a Luer lock. Further preferably, the filter area is formed or delimited by a, preferably elastic, film. The film is preferably made of an artificial or natural polymer or mixed polymer.
In einer weiteren bevorzugten Ausführungsform ist die Vorrichtung eine EinwegVorrichtung.In a further preferred embodiment, the device is a disposable device.
Vorzugsweise ist das Filter ausgebildet, um Serum und/oder Plasma vom Blut abzutrennen. Hierbei findet bevorzugt keine Lyse der Blutzellen statt, die das Messergebnis beeinflussen kann.Preferably, the filter is designed to separate serum and / or plasma from the blood. In this case, preferably no lysis of the blood cells takes place, which can influence the measurement result.
Innerhalb des Filters können Stoffe vorhanden sein, welche Bilirubin, Hämoglobin oder dispergierte Lipide (auch Micellen) entfernen (binden) können. Solche Stoffe können beispielsweise Titandioxide oder Colestyramin sein.Within the filter, there may be substances that can remove (bind) bilirubin, hemoglobin or dispersed lipids (also micelles). Such substances may be, for example, titanium dioxides or colestyramine.
Bei der Bestimmung von DNA können Restmengen an Thrombozyten vorhanden sein, ohne die Messung an sich nachteilig zu beeinflussen. Bei Messungen anderer Bestandteile ist eine vollständige Abtrennung der Thrombozyten von Vorteil, die mit einem Filtersandwich bestehend aus mehreren Lagen unterschiedlicher Filter an entsprechender Stelle in der Vorrichtung erfolgen kann.In the determination of DNA residual amounts of platelets may be present without adversely affecting the measurement itself. For measurements of other components, a complete separation of the platelets is advantageous, which can be done with a filter sandwich consisting of several layers of different filters at the appropriate location in the device.
Bevorzugt ist die Vorrichtung, insbesondere betreffend ihre Abmessungen, mit handelsüblichen Detektionsvorrichtungen kompatibel. Dazu gehören insbesondere handelsübliche Photometer, wie zum Beispiel das Picofluor, TBS380 (Turner Biosystems, USA) oder das Qubit (Invitrogen, USA).Preferably, the device, in particular with respect to their dimensions, compatible with commercially available detection devices. These include, in particular, commercially available photometers, such as, for example, the Picofluor, TBS380 (Turner Biosystems, USA) or the qubit (Invitrogen, USA).
Bevorzugt weist die Vorrichtung und/oder zumindest Teilbereiche der Vorrichtung die Maße einer handelsüblichen Küvette auf und hat vorzugsweise einen Durchmesser von etwa 10mm und/oder eine Länge von etwa 50 mm +/-15 mm oder wird mittels eines Adapters an die Größe einer handelsüblichen Küvette angepasst.Preferably, the device and / or at least portions of the device to the dimensions of a commercially available cuvette and preferably has a diameter of about 10mm and / or a length of about 50 mm +/- 15 mm or by means of an adapter to the size of a commercially available cuvette customized.
Auch bevorzugt weist die Vorrichtung, insbesondere für eine Verwendung mit dem Qubit-Gerät, eine Küvette in Form einer PCR-Tube (bevorzugt mit einem Verwendungsvolumen von 0,5ml) auf.Also preferably, the device, in particular for use with the qubit device, a cuvette in the form of a PCR tube (preferably with a use volume of 0.5 ml) on.
Auch bevorzugt kann die Küvette miniaturisiert sein, z. B. aus einem klarem Röhrchen aus Kunststoff oder Glas bestehen, mit einem Füllvolumen von etwa 20-100 µl, einer Länge von etwa 5-25mm und einem Innendurchmesser von etwa 1-4 mm.Also preferably, the cuvette may be miniaturized, z. B. from a clear tube made of plastic or glass, with a filling volume of about 20-100 ul, a length of about 5-25mm and an inner diameter of about 1-4 mm.
Vorzugsweise weist die Vorrichtung mindestens eine Entlüftungseinrichtung auf. Die Entlüftung findet vorzugsweise mittels einer schmalen Rinne, eines Kanals oder eines Spaltes, vorzugsweise von wenigen mm Länge, statt, welche(r) in die Messkammer mündet bzw. von dieser abgeht und deren/dessen anderes Ende über eine Membrane von der Außenluft beziehungsweise Umgebung getrennt ist. Diese Membran ist vorzugsweise eine semipermeable Membrane welche für Luft bzw. Gas, nicht jedoch wässriges Fluid durchlässig ist. Im Falle der Verwendung einer Küvette ist die semipermeable Membrane besonders bevorzugt am unteren Ende des Röhrchens, vorzugsweise als Verschluss des Röhrchens angebracht.Preferably, the device has at least one venting device. The venting takes place preferably by means of a narrow groove, a channel or a gap, preferably of a few mm length, which (r) opens into the measuring chamber or from this and the other end via a membrane of the outside air or environment is disconnected. This membrane is preferably a semi-permeable membrane which is permeable to air or gas but not aqueous fluid. In the case of using a cuvette, the semipermeable membrane is particularly preferably attached to the lower end of the tube, preferably as a closure of the tube.
Die vorliegende Vorrichtung stellt eine Vorrichtung bereit, die eine integrierte Messkammer mit automatischer Mengenabmessung aufweist. Dabei schließt sich der Messbereich vorzugsweise in Einfüllrichtung bzw. Flussrichtung des Fluids hinter dem Filter an und füllt sich infolge der Konstruktion, Anordnung und Entlüftung vorzugsweise luftblasenfrei mit Filtrat beziehungsweise gefiltertem Fluid auf. Dies erfolgt vorzugsweise in einer genau bestimmbaren und korrekten Menge, passend oder abgestimmt auf die Menge des Detektionsreagenz, so dass nach Befüllung bis zur semipermeablen Membran kein weiterer Fluss stattfinden kann. Dabei ist das Volumen determiniert durch die Volumina der Fluidräume in dem Küvettenteil. Die vorliegende Erfindung erlaubt somit insbesondere eine automatische Mengenabmessung bzw. Mengenvorbestimmung mit dem Vorteil, dass insbesondere pipettieren oder sonstiges Fluidhandling nicht notwendig ist.The present apparatus provides an apparatus having an integrated automatic size measurement chamber. In this case, the measuring range preferably connects in the filling direction or flow direction of the fluid behind the filter and fills due to the design, arrangement and vent preferably free of air bubbles with filtrate or filtered fluid. This is preferably done in a precisely determinable and correct amount, suitable or matched to the amount of Detektionsreagenz so that after filling to the semipermeable membrane no further flow can take place. The volume is determined by the volumes of the fluid spaces in the cuvette part. The present invention thus allows, in particular, an automatic quantity measurement or quantity predetermination with the advantage that in particular pipetting or other fluid handling is not necessary.
Der Messbereich kann auch bereits teilweise vorgefüllt sein, wobei diese Vorfüllung einen Verdünnungspuffer mit einem Detektionsreagenz aufweisen kann. Das verbleibende füllbare Volumen des Messbereichs kann dann mit einer durch das Restvolumen limitierten und damit definierten Menge an gefiltertem Fluid gefüllt und kann nach einer kurzen Inkubationszeit in einem Fluoreszenzphotometer gemessen werden. Nach Abgleich des so erhaltenen Messwertes mit einem Standard unter Berücksichtigung eins Leerwertes (oder Blanks) kann die Menge eines Stoffes, der in dem Fluid enthalten ist, bestimmt werden.The measuring region can also already be partially prefilled, wherein this prefilling can have a dilution buffer with a detection reagent. The remaining fillable volume of the measuring range can then be filled with a quantity of filtered fluid limited by the residual volume and thus defined and can be measured after a short incubation time in a fluorescence photometer. After balancing the measured value thus obtained with a standard taking into account one blank value (or blanks), the amount of a substance that is contained in the fluid can be determined.
In einer weiteren bevorzugten Ausführungsform ist die Entlüftungseinrichtung mit der Messkammer durch eine schmale Rinne oder einen Spalt verbunden, der/die gegenüber der Eingangsöffnung der Messkammer angeordnet ist.In a further preferred embodiment, the venting device is connected to the measuring chamber by a narrow groove or a gap, which is arranged opposite to the inlet opening of the measuring chamber.
Vorzugsweise liegt der Messbereich in Form eines herkömmlichen (PCR-) Röhrchens, weiter bevorzugt mit einer Belüftungseinrichtung, vor bzw. ist als solches ausgebildet, auf das die verbleibende Vorrichtung aufgesteckt ist.Preferably, the measuring range is in the form of a conventional (PCR) tube, more preferably with a ventilation device, before or is designed as such, on which the remaining device is attached.
Vorzugsweise weist die Vorrichtung mindestens einen zweiten Messbereich auf. Damit werden die gleichzeitige Bestimmung von mehreren Messwerten oder die gleichzeitige Bestimmung eines oder mehrerer Eichwerte möglich. Vorzugsweise weist die Vorrichtung mindestens einen weiteren Messbereich zur Bereitstellung eines Leer- bzw. Eichwerts auf.The device preferably has at least one second measuring range. This enables the simultaneous determination of several measured values or the simultaneous determination of one or more calibration values. Preferably, the device has at least one further measuring range for providing a blank or calibration value.
Vorzugsweise interagiert der zu bestimmende Bestandteil mit zwei Detektionsreagenzien. In diesem Falle erfolgt der Nachweis bzw. die Konzentrationsbestimmung mit zwei Detekionsreagenzien in einer Zweischrittreaktion. Dabei interagiert das zuerst bindende Detektionsreagenz spezifisch mit dem zu bestimmenden Bestandteil. Dieses erste Reagenz ist bevorzugt an eine detektierbare Substanz gekoppelt. Die detektierbare Substanz entspricht vorzugsweise einem der obengenannten Fluoreszenzfarbstoffe.Preferably, the component to be determined interacts with two detection reagents. In this case, the detection or the concentration determination is carried out with two detection reagents in a two-step reaction. The first binding detection reagent interacts specifically with the constituent to be determined. This first reagent is preferably coupled to a detectable substance. The detectable substance preferably corresponds to one of the above-mentioned fluorescent dyes.
Vorzugsweise ist das zweite Detektionsreagenz an einen bestimmten Bereich im Messbereich immobilisiert.Preferably, the second detection reagent is immobilized to a certain area in the measurement area.
Vorzugsweise befindet sich das erste Detektionsreagenz in der Vorrichtung in einem Bereich vor dem Messbereich, z.B. in einem dorthin führenden Fluidkanal, Filterbereich oder in einer Mischkammer. Vor Eintritt in den Messbereich soll das Blut bzw. das abgetrennte Plasma oder Serum mit dem ersten Detektionsreagenz in Kontakt gelangen, so dass letzteres an den zu bestimmenden Stoff binden kann. Der Komplex aus zu bestimmendem Stoff und erstem Detektionsreagenz gelangt dann mit dem Plasma oder Serum in den Messbereich, wo er an ein zweites Detektionsreagenz bindet, das in einem bestimmten Bereich des Messbereiches immobilisiert ist. Durch die Akkumulation des Komplexes an dieser Stelle wird der zu bestimmende Bestandteil nachweisbar. Überschüssiges erstes Detektionsreagenz bleibt gleichmäßig im Serum oder Plasma verteilt. Es kann ein Kontrollwert bestimmt werden, der die Konzentration des in der gesamten Lösung verteilten ersten Detektionsreagenzes widerspiegelt. Dieser Kontrollwert kann auch als Schwellen- oder Grenzwert in ein geeignetes Messgerät über eine Software einprogrammiert sein. Im Falle dieser Zweischrittreaktion betrachtet man beide zum Nachweis zugesetzten Reagenzien als Detektionsreagenzien, wobei das erste Detektionsreagenz nicht wie oben beschrieben seine Eigenschaft der Detektierbarkeit bei Bindung des zu bestimmenden Bestandteils ändern muss. Es ist jedoch bevorzugt, dass das erste Detektionsreagenz diese Eigenschaft aufweist. Beide Detektionsreagenzien binden direkt an den zu bestimmenden Bestandteil, so dass der eigentliche Nachweis bzw. die Bestimmung des Bestandteils durch Detektion des ersten Detektionsreagenz erfolgt, während das zweite Detektionsreagenz das Antigen an einer Position fixiert und diese Position nach einer Anreicherung infolge eines finiten Durchströmens mit antigenhaltiger Flüssigkeit einer fotooptischen Messung zugeführt wird.The first detection reagent is preferably located in the device in an area in front of the measuring area, for example in a fluid channel, filter area or in a mixing chamber leading thereto. Before entering the measuring range, the blood or the separated plasma or serum should come into contact with the first detection reagent, so that the latter can bind to the substance to be determined. The complex of the substance to be determined and the first detection reagent then passes with the plasma or serum into the measurement area, where it binds to a second detection reagent which is in a certain range of the measurement range is immobilized. By accumulating the complex at this point, the constituent to be determined becomes detectable. Excess first detection reagent remains evenly distributed in serum or plasma. A control value can be determined which reflects the concentration of the first detection reagent distributed throughout the solution. This control value can also be programmed as a threshold or limit value into a suitable measuring instrument via software. In the case of this two-step reaction, both reagents added for the detection are regarded as detection reagents, whereby the first detection reagent does not have to change its property of detectability upon binding of the constituent to be determined, as described above. However, it is preferred that the first detection reagent has this property. Both detection reagents bind directly to the component to be determined, so that the actual detection or determination of the component by detection of the first detection reagent, while the second detection reagent fixes the antigen at a position and this position after enrichment as a result of a finite flow with antigen-containing Liquid is supplied to a photo-optical measurement.
In dieser Zweischrittreaktion sind die Detektionsreagenzien vorzugsweise Antikörper oder Antikörperfragmente. Im Falle des ersten Detektionsreagenzes ist der Antikörper an eine zu detektierende Substanz gekoppelt. Hierfür eignen sich z.B. R-Phycoerythrin (PE), Fluoresceinisothiocyanat (FITC), PE-Cy5 Allophycocyanin (APC), PE-Texas Red™, Peridinin Chlorophyll Protein (PerCP), PerCP-Cy5.5, APC-Cy7, und/oder Texas Red™, usw.In this two-step reaction, the detection reagents are preferably antibodies or antibody fragments. In the case of the first detection reagent, the antibody is coupled to a substance to be detected. For example, R-phycoerythrin (PE), fluorescein isothiocyanate (FITC), PE-Cy5 allophycocyanin (APC), PE-Texas Red ™ , Peridinin Chlorophyll Protein (PerCP), PerCP-Cy5.5, APC-Cy7, and / or Texas Red ™ , etc.
In einer Zweischrittreaktion zu bestimmende Bestandteile sind zum Beispiel körpereigene Stoffe wie Interleukin 6 (IL-6), Hämoglobin, Bilirubin, CRP, Lactoferrin, Procalcitonin, AT-III, Protein C, p24 (HIV) oder Antikörper. Auch körperfremde Stoffe wie Viren, Bakterien, Medikamente, Gifte, Drogen oder Fragmente der genannten Stoffe können so zur Bestimmung gelangen.Components to be determined in a two-step reaction are, for example, endogenous substances such as interleukin 6 (IL-6), hemoglobin, bilirubin, CRP, lactoferrin, procalcitonin, AT-III, protein C, p24 (HIV) or antibodies. Even foreign substances such as viruses, bacteria, drugs, toxins, drugs or fragments of the substances mentioned can thus be determined.
Die erfindungsgemäße Vorrichtung ermöglicht so die qualitative und/oder quantitative Bestimmung eines Blutbestandteils, insbesondere ohne weitere, manuelle oder labortechnische Arbeitsschritte.The device according to the invention thus enables the qualitative and / or quantitative determination of a blood component, in particular without further, manual or laboratory work steps.
Die vorliegende Erfindung bezieht sich außerdem auf ein Verfahren zum Nachweis, insbesondere zur Bestimmung der Konzentration, von Bestandteilen in Blut, vorzugsweise unter Verwendung einer Vorrichtung der vorliegenden Erfindung. Das Verfahren umfasst die Schritte (a) Bereitstellen einer Vorrichtung aufweisend einen Messbereich, ein Filter und ein Detektionsreagenz, (b) Einbringen eines Fluids in die Vorrichtung, und (c) Nachweisen des bzw. Messen der Konzentration des Bestandteils unter Verwendung der Vorrichtung. Der Schritt des Nachweisens des bzw. Messens der Konzentration des Bestandteils erfolgt vorzugsweise unter Verwendung einer herkömmlichen Messeinrichtung, vorzugsweise ein Fluoreszenzphotometer.The present invention also relates to a method for detecting, in particular, for determining the concentration of constituents in blood, preferably using a device of the present invention. The method comprises the steps of (a) providing a device comprising a measurement region, a filter and a detection reagent, (b) introducing a fluid into the device, and (c) detecting the concentration of the component using the device. The step of detecting the concentration of the component is preferably carried out using a conventional measuring device, preferably a fluorescence photometer.
Die vorliegende Erfindung bezieht sich außerdem auf die Verwendung einer Vorrichtung bzw. eines Verfahrens der vorliegenden Erfindung zur Bestimmung von Bestandteilen in Blut, wie z.B., Bilirubin, freiem Hämoglobin, IL-6 oder p24 (HIV-Protein), CRP. Weiter bevorzugt ist die Verwendung zur Bestimmung von zellfreier DNA. Hämoglobin oder Bilirubin wird vorzugsweise gemessen durch Messung der Photoabsorption bei Verwendung geeigneter Wellenlängen oder auch durch Messung der charakteristischen Eigenfluoreszenz dieser Stoffe.The present invention also relates to the use of a device or method of the present invention for determining constituents in blood, such as, bilirubin, free hemoglobin, IL-6 or p24 (HIV protein), CRP. Further preferred is the use for the determination of cell-free DNA. Hemoglobin or bilirubin is preferably measured by measuring the photoabsorption using appropriate wavelengths or by measuring the intrinsic characteristic fluorescence of these substances.
Die vorliegende Erfindung bezieht sich weiterhin auf ein Kit, umfassend mindestens eine Vorrichtung gemäß der vorliegenden Erfindung, und einen (Fluoreszenz-) Standard der z. B. DNA enthalten kann. Der Kit umfasst weiterhin vorzugsweise eine Spritze, vorzugsweise mit Zubehör zur Entnahme von Blut von einem Patienten, und/oder eine Messeinrichtung. Weiterhin umfasst der Kit vorzugsweise eine Bedienungsanleitung mit Interpretationshilfen. Die Messeinrichtung kann weiterhin ein Gerät umfassen, welches besonders zur Messung der Proben, welche mit der Vorrichtung hergestellt wurden, geeignet ist. Dazu kann eine Software gehören, welche eine Speicherung und Verwaltung der Daten erlaubt. Hierzu kann ein Adapterkabel gehören. Es kann weiter ein Batteriepack dazugehören, welches netzunabhängige Messungen ermöglicht.The present invention further relates to a kit comprising at least one device according to the present invention, and a (fluorescence) standard of e.g. B. may contain DNA. The kit preferably further comprises a syringe, preferably with accessories for taking blood from a patient, and / or a measuring device. Furthermore, the kit preferably comprises a manual with interpretation aids. The measuring device may further comprise a device, which is particularly suitable for measuring the samples which were produced with the device. This may include software that allows storage and management of the data. This may include an adapter cable. It may further include a battery pack that allows off-grid measurements.
Im Folgenden werden bevorzugte Ausführungsformen der vorliegenden Erfindung unter Bezugnahme auf die Figuren beschrieben. Hierbei zeigen:
Figur 1- eine bevorzugte Ausführungsform einer erfindungsgemäßen Vorrichtung mit einem Messbereich wobei
Figur 1a eine schematische Draufsicht der Vorrichtung undFigur 1b einen schematischen Schnitt in einer Seitenansicht der bevorzugten Vorrichtung zeigt; - Figur 2
- eine schematische Draufsicht auf eine bevorzugte erfindungsgemäße Ausführungsform einer Vorrichtung mit zwei parallelen Messbereichen;
Figur 3- eine schematische Draufsicht auf eine weitere bevorzugte erfindungsgemäße Ausführungsform einer Vorrichtung mit zwei Messbereichen;
- Figur 4
- eine schematische Draufsicht auf eine bevorzugte erfindungsgemäße Ausführungsform einer Vorrichtung mit drei Messbereichen;
Figur 5- schematische Draufsichten auf weitere bevorzugte Ausführungsformen der vorliegenden Erfindung, wobei
Figur 5a eine bevorzugte Ausführungsform mit einem flußoptimierten Messbereich undFigur 5b eine bevorzugte Ausführungsform mit anders flußoptimierten Messbereich darstellen; - Figur 6
- eine schematische Draufsicht auf eine bevorzugte erfindungsgemäße Ausführungsform einer Vorrichtung mit integriertem Immunassay mit einem Plasma Reservoir;
Figur 7- eine schematische Ansicht einer bevorzugten erfindungsgemäßen Vorrichtung mit einem scheibenförmig ausgeführten Filter, wobei
Fig. 7a eine schematische Draufsicht auf die Vorrichtung darstellt undFig. 7b eine schematische Ansicht der Vorrichtung gemäßFig. 7a aus Sicht von oben inFig. 7a ;Figur 8 eine schematisch Draufsicht auf eine bevorzugte erfindungsgemäße Ausführungsform einer Vorrichtung; Figur 9- eine schematisch Draufsicht auf eine bevorzugte erfindungsgemäße Ausführungsform einer Vorrichtung;
- Figur10
- eine schematisch Draufsicht auf eine bevorzugte erfindungsgemäße Ausführungsform einer Vorrichtung; und
- Figur11
- eine schematisch Draufsicht auf eine bevorzugte erfindungsgemäße Ausführungsform einer Vorrichtung.
- FIG. 1
- a preferred embodiment of a device according to the invention with a measuring range
FIG. 1a a schematic plan view of the device andFIG. 1b shows a schematic section in a side view of the preferred device; - FIG. 2
- a schematic plan view of a preferred embodiment of a device according to the invention with two parallel measuring ranges;
- FIG. 3
- a schematic plan view of another preferred embodiment of the invention of a device with two measuring ranges;
- FIG. 4
- a schematic plan view of a preferred embodiment according to the invention of a device with three measuring ranges;
- FIG. 5
- schematic plan views of further preferred embodiments of the present invention, wherein
FIG. 5a a preferred embodiment with a flow-optimized measuring range andFIG. 5b represent a preferred embodiment with differently flow-optimized measuring range; - FIG. 6
- a schematic plan view of a preferred embodiment of an integrated immunoassay device according to the invention with a plasma reservoir;
- FIG. 7
- a schematic view of a preferred device according to the invention with a disc-shaped filter, wherein
Fig. 7a represents a schematic plan view of the device andFig. 7b a schematic view of the device according toFig. 7a from above from aboveFig. 7a ;FIG. 8 a schematic plan view of a preferred embodiment of an apparatus according to the invention; - FIG. 9
- a schematic plan view of a preferred embodiment of an apparatus according to the invention;
- Figur10
- a schematic plan view of a preferred embodiment of an apparatus according to the invention; and
- Figur11
- a schematic plan view of a preferred embodiment of an apparatus according to the invention.
Die erfindungsgemäße Vorrichtung, wie beispielsweise in
Die Vorrichtung nach
Der Filterbereich 5 ist vorzugsweise elastisch und beutelartig ausgebildet und weiterhin oder zusätzlich vorzugsweise aus weichem PVC, PE, einem Misch- oder auch Compositpolymer. Die Öffnung 9 ist vorzugsweise derart ausgebildet, beispielsweise durch Ausbildung als Luer-Lock, dass eine handelsübliche Spritze (nicht dargestellt) mit ihr verbunden werden kann. Beispielsweise wird durch eine solche Spritze eingefülltes Fluid, insbesondere Blut, über die Öffnung 9 und gegebenenfalls den Schlauch 11 in den Filterbereich 5 eingebracht. Hierbei ist der Filterbereich 5 vorzugsweise derart ausgebildet, dass er beim Einbringen einer bestimmten Menge bzw. eines bestimmten Volumens an Fluid eine vorbestimmte Dehnung erfährt, die wiederum einen bestimmten Druck auf den Innenraum des Filterbereichs 5 bedingt. Materialien, einzubringendes bzw. benötigtes Volumen und dergleichen sind vorzugsweise dementsprechend aufeinander abgestimmt. Die Ausbildung der Öffnung 9 mit einem Ein-Wege-Ventil verhindert das Austreten des unter Druck stehenden, im Fluideingangsbereich des bzw. Filterbereich(s) 5 vorhandenen Fluids.The
Durch den nun im Filterbereich 5 herrschenden Druck wird das in ihm enthaltene Fluid durch ein Filter, vorzugsweise eine Spezialmembran, die weiterhin bevorzugt in den Filterbereich 5 eingeschweißt ist, gedrückt.As a result of the pressure now prevailing in the
Neben der Öffnung 9 weist der Filterbereich 5 vorzugsweise einen Ausgang auf, der in den Fluidkanal 7 mündet, der wiederum zum Messbereich 3 führt. Vorzugsweise ist das Filter derart angeordnet, dass das im Filterbereich 5 vorhandene, unter Druck stehende Fluid durch das Filter (nicht dargestellt) in den Fluidkanal 7 und damit in den Messbereich 3 transportiert wird. Das so gefilterte Fluid, vorzugsweise das Blutplasma und insbesondere vorzugsweise ein vorbestimmtes Volumen an Blutplasma wird so in der Messkammer 3 bereitgestellt.In addition to the
Das vorgenannte gilt in Analogie ebenso für die bevorzugten Ausführungsformen nach
Die Vorrichtung weist ferner ein Detektionsreagenz, vorzugsweise Pico-Green™ auf, das in der Messkammer 3 und/oder im Fluidkanal 7 derart vorgesehen ist, dass es mit dem durch den Fluidkanal fließenden Blutplasma oder Serum und/oder mit dem in der Messkammer 3 gesammelten Blutplasma oder Serum in Kontakt kommt und insbesondere interagiert, vorzugsweise derart, dass ein Nachweis, insbesondere eine Bestimmung der Konzentration von Bestandteilen im Fluid bzw. Blutplasma, ermöglicht wird.The apparatus further comprises a detection reagent, preferably Pico-Green ™ , which is provided in the measuring
Hierzu sind die Vorrichtung und insbesondere die Volumina von Messbereich 3, Filterbereich 5 und Fluidkanal 7 (respektive Teil 17) sowie die Eigenschaften des Filterbereichs 5 hinsichtlich Elastizität und Druckaufbau sowie des Filters hinsichtlich der Filter- und Durchlasseigenschaften derart aufeinander abgestimmt, dass in der Messkammer 3 beziehungsweise im Fluidkanal 7 (respektive Teil 17) eine vorbestimmte Menge an Blutplasma vorhanden ist, die mit einer vorbestimmten Menge an Detektionsreagenz interagiert.For this purpose, the device and in particular the volumes of measuring
Vorzugsweise ist die Messkammer 3 und/oder der Fluidkanal 7 (respektive Teil 17) auf ihrem, mit dem Blutplasma in Verbindung tretenden Innenbereich, zumindest teilweise mit einem Detektionsreagenz, welches vorzugsweise Pico-Green™ oder SytoxGreen enthält oder daraus besteht, beschichtet. Weiter kann auch ein schnell lösliches Pellet, das ein Detektionsreagenz aufweist, im Bereich der Messkammer 3 oder der Fluidkanal 7 (respektive Teil 17) positioniert werden.The measuring
Vorzugsweise geht vom Messbereich 3 ein Kanal, vorzugsweise ein Lüftungskanal 13 ab. Ein solcher Kanal mündet vorzugsweise in einer Entlüftungsöffnung bzw. Entlüftungsaussparung oder Vertiefung 15, die vorzugsweise im Außenbereich der Vorrichtung angeordnet ist und mit einer semipermeablen Membran (nicht dargestellt) gegenüber der Umgebung abgedichtet ist. Eine derartige Membran weist vorzugsweise die Eigenschaft auf, dass sie von der Innenseite der Vorrichtung her gesehen für Luft bzw. gasförmige Medien durchlässig ist, nicht aber für flüssige Medien bzw. Blutplasma. Dementsprechend sind der Kanal und der Entlüftungsbereich 15 dazu ausgebildet, beim Befüllen des Filterbereichs 5 bzw. des Fluidkanals 7 und des Messbereichs 3 in der Vorrichtung 1 vorhandene überschüssige Luft nach außen in die Umgebung abzuführen, in anderen Worten, um die Vorrichtung 1 zu entlüften. Dies erlaubt vorteilhafter Weise insbesondere das Einbringen eines definierten Flüssigkeitsvolumens in den Messbereich.Preferably, a channel, preferably a
Die erfindungsgemäße Vorrichtung 1 erlaubt somit das automatische Füllen des Messbereichs 3 mit einer definierten Menge an Blutplasma und das Mischen mit einem Detektionsreagenz. Die Vorrichtung und das im Messbereich vorliegende Fluid, vorzugsweise Blutplasma, sind insbesondere einer photooptischen Erfassung zugänglich. Gemäß der obigen Beschreibung beispielsweise zum Zwecke der Erfassung freier DNA mittels eines interkalierenden Fluoreszenzfarbstoffes wie beispielsweise Pico-Green™.The
Das Detektionsreagenz ist vorzugsweise auf die Innenseite der Messkammer 5 oder des Meßkanals aufgetragen, vorzugsweise via Tintenstrahl, und getrocknet. Alternativ oder zusätzlich wird das Detektionsreagenz als Staub oder Pellet in der Messkammer vorliegend oder beispielsweise innerhalb der Zuflussrinne als leicht lösliches Material vorgesehen. Die Vorrichtung weist vorzugsweise einen Durchmesser von etwa 10mm und eine Länge bzw. Höhe von etwa 50 mm +/- 15 mm auf.The detection reagent is preferably applied to the inside of the measuring
Der Messbereich ist vorzugsweise zumindest teilweise durchsichtig bzw. durchscheinend ausgebildet, insbesondere um eine optische Erfassung des nachzuweisenden bzw. zu bestimmenden Bestandteils, vorzugsweise mittels einer Fluoreszenzmessung, zu gewährleisten.The measuring area is preferably at least partially transparent or translucent, in particular in order to ensure an optical detection of the component to be detected or determined, preferably by means of a fluorescence measurement.
Die vorangegangene Beschreibung, die insbesondere unter Bezug auf
Die vorangegangene Beschreibung, die insbesondere unter Bezug auf
Vorzugsweise ist mindestens einer der Messbereiche, auch als Leerwert-Messbereich bezeichnet, zur Bestimmung eines Leerwertes vorgesehen. Ein Leerwert oder Nullwert ist ein Wert, der zum Vergleich der zu messenden Probe herangezogen wird. Beispielsweise kann als Leerwert gefiltertes Blutplasma ohne Reagenz in dem Leerwert-Messbereich gemessen werden, welches dann etwa eine Autofluoreszenz angibt. Ein Eichwert kann gebildet werden vorzugsweise mit der Messung eines Fluids der gleichen Art, welches mit standardisierten Mengen der zu messenden Substanz versetzt ist. Weiter bevorzugt kann ein Eichwert gebildet werden durch Messung einer Küvette, welche beispielsweise mit einer dem Blutplasma in optischer Hinsicht ähnlichen Flüssigkeit oder aber auch einem Kunststoff gefüllt ist/besteht und eine stabile definierte Fluoreszenz aufweist. Basierend auf diesen Werten wird der entsprechende Messwert der Probe(n) evaluiert. So kann man z. B. täglich eine Standardmessung vornehmen und vom Patienten jeweils einen Leerwert und einen Messwert des interessierenden Analyts vornehmen.Preferably, at least one of the measuring ranges, also referred to as a blank value measuring range, is provided for determining a blank value. A blank or zero value is a value used to compare the sample to be measured. For example, blood plasma filtered as a blank can be measured without reagent in the blank measurement range, which then indicates approximately autofluorescence. A calibration value can be formed, preferably with the measurement of a fluid of the same type, which is mixed with standardized amounts of the substance to be measured. More preferably, a calibration value can be formed by measuring a cuvette, which is filled, for example, with a fluid that is optically similar to the blood plasma or else a plastic and has a stable, defined fluorescence. Based on these values, the corresponding measured value of the sample (s) is evaluated. So you can z. B. make a standard daily measurement and make each of the patient a blank and a reading of the analyte of interest.
Die entsprechenden bevorzugten Ausführungsformen erlauben somit das gleichzeitige Durchführen paralleler, identischer Messungen oder aber paralleler unterschiedlicher Messungen. Wie bereits im Zusammenhang mit der bevorzugten Vorrichtung der Messfigur 1 beschrieben sind auch bei den bevorzugten Ausführungsformen wie in
Auch _
Die vorliegende Erfindung stellt somit eine vorteilhafte Vorrichtung, Verfahren sowie ein Kit bereit, die die Nachteile des Standes der Technik überwinden. Insbesondere erlaubt die vorliegende Erfindung die Trennung von Plasma oder Serum von Vollblut und eine Analyse von im Serum oder Plasma befindlichen Stoffen durchzuführen, ohne dass Zentrifugationsschritte oder ähnliche labortechnische Verarbeitungsschritte des gewonnenen Serums oder Plasmas notwendig sind. Weiterhin stellt die vorliegende Erfindung eine Vorrichtung, ein Verfahren und ein Kit bereit, die einfach, sicher und zuverlässig zu handhaben bzw. durchzuführen sind, und sich insbesondere zur Verwendung bzw. Durchführung durch Laien bzw. nicht medizinisch geschultes Personal eignen sowie einfach und kostengünstig herzustellen, durchzuführen und/oder zu Lagern ist.The present invention thus provides an advantageous apparatus, methods and kit that overcomes the disadvantages of the prior art. In particular, the present invention allows separation of plasma or serum from whole blood and analysis of serum or plasma without the need for centrifugation or similar laboratory processing steps of the recovered serum or plasma. Furthermore, the present invention provides a device, a method and a kit that are easy to handle, safe and reliable, and are particularly suitable for use by laymen or non-medically trained personnel as well as simple and inexpensive to manufacture to perform and / or store.
Claims (35)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07021342A EP2055384A1 (en) | 2007-10-31 | 2007-10-31 | Device for identifying constituents in a fluid |
| JP2010531462A JP2011501201A (en) | 2007-10-31 | 2008-10-31 | Device for detecting components in a liquid |
| CN2008801144648A CN101883634A (en) | 2007-10-31 | 2008-10-31 | Device for identifying constituents in a fluid |
| EP08845028A EP2205355A2 (en) | 2007-10-31 | 2008-10-31 | Device for the detection of components in a fluid |
| PCT/EP2008/009219 WO2009056340A2 (en) | 2007-10-31 | 2008-10-31 | Device for the detection of components in a fluid |
| US12/740,817 US20100261223A1 (en) | 2007-10-31 | 2008-10-31 | Device for detecting components in a fluid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07021342A EP2055384A1 (en) | 2007-10-31 | 2007-10-31 | Device for identifying constituents in a fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2055384A1 true EP2055384A1 (en) | 2009-05-06 |
Family
ID=39154030
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP07021342A Withdrawn EP2055384A1 (en) | 2007-10-31 | 2007-10-31 | Device for identifying constituents in a fluid |
| EP08845028A Withdrawn EP2205355A2 (en) | 2007-10-31 | 2008-10-31 | Device for the detection of components in a fluid |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP08845028A Withdrawn EP2205355A2 (en) | 2007-10-31 | 2008-10-31 | Device for the detection of components in a fluid |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100261223A1 (en) |
| EP (2) | EP2055384A1 (en) |
| JP (1) | JP2011501201A (en) |
| CN (1) | CN101883634A (en) |
| WO (1) | WO2009056340A2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011051405A1 (en) * | 2009-10-30 | 2011-05-05 | Dublin City University | Microfludic device providing degassing driven fluid flow |
| DE102009045404B4 (en) * | 2009-10-06 | 2012-04-19 | INSTITUT FüR MIKROTECHNIK MAINZ GMBH | Discharge channel and microfluidic structure and method for measuring and / or positioning a volume of a liquid |
| CN104880442A (en) * | 2015-05-21 | 2015-09-02 | 桂林理工大学 | Method for determining dopamine hydrochloride |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2494653A (en) * | 2011-09-13 | 2013-03-20 | Orreco Ltd | Apparatus for blood analysis |
| RU2645091C2 (en) * | 2012-08-08 | 2018-02-15 | Конинклейке Филипс Н.В. | Method and device for plasma separation from blood for bilirubin content assessment |
| AT513559B1 (en) * | 2012-11-06 | 2016-02-15 | Gerhard Bonecker | Photometric measuring device and photometric measuring method for a sample liquid |
| US9386948B2 (en) | 2012-12-05 | 2016-07-12 | Theranos, Inc. | Systems, devices, and methods for bodily fluid sample transport |
| US10248765B1 (en) | 2012-12-05 | 2019-04-02 | Theranos Ip Company, Llc | Systems, devices, and methods for bodily fluid sample collection, transport, and handling |
| WO2014145330A2 (en) * | 2013-03-15 | 2014-09-18 | Theranos, Inc. | Methods and devices for sample collection and sample separation |
| CN103323590B (en) * | 2013-06-08 | 2015-05-06 | 上海云泽生物科技有限公司 | Quantitative detection device based on fibrous-membrane gathering and separation and detection method thereof |
| EP3078956A4 (en) * | 2013-12-03 | 2017-06-28 | The University of Tokyo | Separation unit, separation method, fluid device, and composite fluid device and kit |
| CN105772117A (en) * | 2014-12-22 | 2016-07-20 | 卡梅德生物科技(天津)有限公司 | Experimental chip used for detection of chemical components in biological laboratory |
| US10371606B2 (en) | 2015-07-21 | 2019-08-06 | Theraos IP Company, LLC | Bodily fluid sample collection and transport |
| WO2017044888A1 (en) | 2015-09-09 | 2017-03-16 | Theranos, Inc. | Methods and devices for sample collection and sample separation |
| JP6874432B2 (en) * | 2017-03-10 | 2021-05-19 | 東洋紡株式会社 | Immunochromatographic test piece |
| US11857966B1 (en) | 2017-03-15 | 2024-01-02 | Labrador Diagnostics Llc | Methods and devices for sample collection and sample separation |
| US11287404B2 (en) * | 2017-12-21 | 2022-03-29 | International Business Machines Corporation | Analysis apparatus with spectrometer |
| CN113933129B (en) * | 2021-09-14 | 2024-01-12 | 深圳大学 | Preeclampsia diagnosis kit and application of fluorescent dye |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996000614A1 (en) * | 1994-06-30 | 1996-01-11 | Zia Yassinzadeh | Sample collection and manipulation apparatus and method |
| EP0974840A2 (en) * | 1998-07-20 | 2000-01-26 | Lifescan, Inc. | Fluidic device for medical diagnostics |
| WO2006009724A2 (en) * | 2004-06-17 | 2006-01-26 | Micronics, Inc. | Microfluidic devices for fluid manipulation and analysis |
| US20060228259A1 (en) * | 2005-04-12 | 2006-10-12 | Chromodex Inc. | Joint-diagnostic spectroscopic and biosensor meter |
| US20070031283A1 (en) * | 2005-06-23 | 2007-02-08 | Davis Charles Q | Assay cartridges and methods for point of care instruments |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS544121Y2 (en) * | 1974-07-05 | 1979-02-23 | ||
| US4816224A (en) * | 1980-08-05 | 1989-03-28 | Boehringer Mannheim Gmbh | Device for separating plasma or serum from whole blood and analyzing the same |
| US5186843A (en) * | 1991-07-22 | 1993-02-16 | Ahlstrom Filtration, Inc. | Blood separation media and method for separating plasma from whole blood |
| CA2155642A1 (en) * | 1993-12-22 | 1995-06-29 | Shmuel Sternberg | Methods for characterizing complex filtration media |
| US6251660B1 (en) * | 1997-11-25 | 2001-06-26 | Mosaic Technologies, Inc. | Devices and methods for detecting target molecules in biological samples |
| JP3833830B2 (en) * | 1998-09-01 | 2006-10-18 | 富士写真フイルム株式会社 | Blood component separator |
| US6436121B1 (en) * | 2001-04-30 | 2002-08-20 | Paul H. Blom | Removable blood filter |
| EP1580551B1 (en) * | 2002-11-19 | 2013-02-20 | Sekisui Medical Co., Ltd. | Plasma or serum separation membrane and filter apparatus including the plasma or serum separation membrane |
-
2007
- 2007-10-31 EP EP07021342A patent/EP2055384A1/en not_active Withdrawn
-
2008
- 2008-10-31 CN CN2008801144648A patent/CN101883634A/en active Pending
- 2008-10-31 JP JP2010531462A patent/JP2011501201A/en active Pending
- 2008-10-31 US US12/740,817 patent/US20100261223A1/en not_active Abandoned
- 2008-10-31 WO PCT/EP2008/009219 patent/WO2009056340A2/en active Application Filing
- 2008-10-31 EP EP08845028A patent/EP2205355A2/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996000614A1 (en) * | 1994-06-30 | 1996-01-11 | Zia Yassinzadeh | Sample collection and manipulation apparatus and method |
| EP0974840A2 (en) * | 1998-07-20 | 2000-01-26 | Lifescan, Inc. | Fluidic device for medical diagnostics |
| WO2006009724A2 (en) * | 2004-06-17 | 2006-01-26 | Micronics, Inc. | Microfluidic devices for fluid manipulation and analysis |
| US20060228259A1 (en) * | 2005-04-12 | 2006-10-12 | Chromodex Inc. | Joint-diagnostic spectroscopic and biosensor meter |
| US20070031283A1 (en) * | 2005-06-23 | 2007-02-08 | Davis Charles Q | Assay cartridges and methods for point of care instruments |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009045404B4 (en) * | 2009-10-06 | 2012-04-19 | INSTITUT FüR MIKROTECHNIK MAINZ GMBH | Discharge channel and microfluidic structure and method for measuring and / or positioning a volume of a liquid |
| WO2011051405A1 (en) * | 2009-10-30 | 2011-05-05 | Dublin City University | Microfludic device providing degassing driven fluid flow |
| CN104880442A (en) * | 2015-05-21 | 2015-09-02 | 桂林理工大学 | Method for determining dopamine hydrochloride |
| CN104880442B (en) * | 2015-05-21 | 2017-10-10 | 桂林理工大学 | A kind of method for determining Dopamine hydrochloride |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100261223A1 (en) | 2010-10-14 |
| JP2011501201A (en) | 2011-01-06 |
| WO2009056340A2 (en) | 2009-05-07 |
| CN101883634A (en) | 2010-11-10 |
| WO2009056340A3 (en) | 2009-11-05 |
| EP2205355A2 (en) | 2010-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2055384A1 (en) | Device for identifying constituents in a fluid | |
| DE69033796T2 (en) | METHOD AND DEVICE FOR DETECTING AND QUANTIFYING GLUCOSE IN BODY LIQUIDS | |
| DE69432122T2 (en) | METHOD AND DEVICE FOR DETECTING HEMOLYSIS IN LIQUID SAMPLES | |
| DE68916458T2 (en) | Method and device for separating a body fluid from particles in this fluid and test kit for this separation and analysis of the body fluid. | |
| DE60113703T2 (en) | STRIP HOLDER FOR USE IN A TEST STRIP METER | |
| DE69922355T2 (en) | ANALYSIS OF RESTING WHOLE TREATED TREATMENTS TREATED WITH ANTIKOAGULANS | |
| DE60035199T2 (en) | ANALYSIS CASSETTE AND LIQUID CONVEYOR CONTROLLER | |
| DE10204606C1 (en) | Device and method for high density lipoproteins | |
| EP0106339A2 (en) | Method for the quantitative simultaneous determination of cells, and reagent therefor | |
| EP2179053B1 (en) | Determination of the activity of proteases | |
| EP2533740B1 (en) | Dressing material for monitoring a wound healing | |
| US10345237B1 (en) | Spectral edge detection | |
| EP3646029B1 (en) | Detection system and process for its production | |
| DE102012201390B4 (en) | Sensor arrangement for a vacuum therapy system and vacuum therapy system with sensor functionality | |
| EP4384802B1 (en) | Method for creating a database for determining a light transmission aggregometry reference value, and method and device for carrying out a light transmission aggregometry measurement | |
| EP1269213A2 (en) | Method for the esr-spectroscopic detection of changes in the transport properties of albumin in an albumin-containing sample, esr-spectrometer for carrying out said method, and use of the method for diagnostic purposes and for controlling albumin-containing preparations | |
| US10753875B1 (en) | Spectral unmixing of spectroscopic emission images | |
| DE10331108B4 (en) | Universally applicable test container for sterile analysis and its use | |
| CN109601010A (en) | Solution for sample processing | |
| US20180299442A1 (en) | Enrichment and identification of fetal material | |
| WO2025059475A1 (en) | Methods, systems, and devices for using autofluorescence to probe cellular characteristics | |
| WO2017036999A1 (en) | Device and method for the optical stimulation of an optically activatable biological sample | |
| DE102024108879A1 (en) | Mobile device and method for analyzing a fluid, especially cerebrospinal fluid | |
| WO2006056001A1 (en) | Device for qualitatively and quantitatively analyzing analytes | |
| DE10103196A1 (en) | Absorption and storing of specimens of body fluid for diagnostic purposes comprises applying specimen to soluble microporous substrate, both substrate and specimen being dissolved and analysis carried out on solution produced |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
| AKX | Designation fees paid | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20091107 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: 8566 |